Results of COVID-19 Vaccine Effectiveness Studies: An Ongoing Systematic Review

Duration of Protection Weekly Summary Table

Updated May 19, 2022

Prepared by:

International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health

and

World Health Organization

and

Coalition for Epidemic Preparedness Innovations







For comments or questions, please contact: Anurima Baidya at abaidya1@jhmi.edu or Karoline Walter at kwalte21@jhmi.edu





Duration of Protection Studies

These are studies that assess duration of protection criteria as outlined above along with those studies that do not meet aforementioned criteria that are relevant to evaluating duration of protection. Some of these studies are also in the above table but duplicated here for ease. As of April 28, 2022, those studies that provide VE estimates at least 4 months after the primary series or at least 2 months after the booster series are included below.

We would like to highlight

- Countries have implemented different dose intervals and vaccination strategies that can make comparisons across studies challenging.
- Persons who are vaccinated early in a program are different than those who are vaccinated later. For example, many who were vaccinated early were those at highest risk, and this could confound the results. Some of the older individuals also might have some degree of immunosenescence.

#	Reference (date)	Country	Population	Dominant Variants	Vaccine product	Study Period	Descriptive Findings
166	<u>Fano et al</u> (May 18, 2022)	Italy	12+ year olds	Alpha, Delta, Omicron	ChAdOx1 Comirnaty mRNA-1273 Ad26.COV2.S	January 1, 2021- January 10, 2022	Cohort study conducted by linking administrative databases evaluating VE against infection. Figure 2 - Adjusted 'vacuus effectiveness (VE) against BAB-CoV2 infection at different time after the administration of the second does and the booster does. Reference: uvaccinated. 000 000 000 000 000 000 000





165	Tenforde et al (May 17, 2022)	USA	General population	Pre-Omicron	Comirnaty mRNA-1273	March 11- December15, 2021	TND study evaluating 2-dose VE against hopsitalization.
164	<u>Braeve et al</u> (May 11, 2022)	Belgium	18+ year olds	Delta, Omicron	ChAdOx1 Comirnaty mRNA-1273 Ad26.COV2.S	Delta: July 15, 2021- December 6, 2021 Omicron: January 3, 2022-April 14, 2022	<figure><figure></figure></figure>
163	<u>Butt et al</u> (May 3, 2022)	USA	Veterans	Omicron	Comirnaty mRNA-1273	January 1-February 20, 2022	Cohort study among veterans. Relative vaccine effectiveness was highest for patients receiving their booster vaccine within 28 days of the start of the period of omicron predominance (RVE=40% [35-44%] for BNT-162b2; RVE=30% [23-36%] for mRNA-1273), and protection against infection was negligible for both vaccines for patients with 4 or more months since receiving the booster vaccination. Relative vaccine effectiveness for hospitalizations remained above 44% for all groups.







162	<u>Amir et al</u> (May 5, 2022)	Israel	60+ year olds	Omicron	Comirnaty	January 16, 2022, to March 12, 2022	Cohort study b	oy linking adminsitrat	ive databa	ises evaluating r	relative VE agains	t severe disease.
									VE	LCI	UCI	
							2nd dose	4+ months		ref		
								0-1 month	57%	38%	71%	
								1-2 months	66%	44%	79%	
							ose	2-3 months	68%	55%	78%	
							3rd dose	3-4 months	67%	58%	73%	
							310	4-5 months	64%	60%	70%	
								5-6 months	64%	60%	69%	
								6-7 months	68%	58%	76%	
							4th dose	0-2 months	89%	87%	91%	
161		South Africa	HCW	Omicron	Comirnaty	November 15, 2021-		ducted as part of Sise		Note that the	y evaluated VE of	2 doses of
	(May 4, 2022)				Ad26.COV2.S	January 14, 2022		2 doses of Ad26.CO				
							0-13 100 -	3 Days 14–27 D	Days	1–2 Mo	3–4 Mo	≥5 Mo
							90- 80- 50- 50- 30- 20- 10-	81 1 74 88	69	172 170 70 70 70 70	₹ ⁷¹ ₹ ⁷	3 He2 H21
							Hospital Hig	h Care Hospital High C	are Hosp	pital High Care	84 ^{116¹⁰²} 84 ^{116¹⁰²} Hospital High Car Admission or ICU	
							Admission of	r ICU Admission or IC	U Admi	ssion or ICU	Admission or ICU	Admission or ICU







160	Castillo et al	France	18+ year olds	Delta,	Comirnaty	December 13, 2021 –					s VE against	symptomat	ic disease, with
	(April 21, 2022)			Omicron	mRNA-1273	January 31, 2021	cohort study d	one among	•	alized cases.	1	0-1	
							Immune status: time	Risk reduc	Omicron ^a tion ^c against	Protection 1- OR×HR	Risk reduc	Deltaª :lon ^c against	Protection
							since named vaccine dose ⁶	Symptomatic Infection	Hospital admission among symptomatic cases	Protection(95%CI)	Symptomatic Infection	Hospital admission among symptomatic cases	Protection (95%Cl)
								OR4 (95%CI)	HR [®] (95%CI)		OR4 (95%CI)	HR* (95%CI)	
							Vaccinated (ref.: unvac	cinated without pri)			
							D1: 0 day-28 days	0.88 (0.86 to 0.91)	0.99 (0.75t0 1.23)	0.12 (-0.09 to 0.34)	0.62 (0.59t00.66)	0.66 (0.50 to 0.81)	0.59 (0.49 to 0.69)
							D2: o days- 30 days	0.57 (0.55 to 0.59)	0.72 (0.50 to 0.95)	0.59 (0.46 to 0.72)	0.22 (0.20100.23)	0.40 (0.23t0 0.57)	0.91 (0.87to 0.95)
							D2:1month-2months	0.68 (0.66 to 0.70)	0.40 (0.27 to 0.53)	0.73 (0.64 to 0.82)	0.30 (0.28t0 0.31)	0.41 (0.25 to 0.57)	0.88 (0.83 to 0.93)
							D2: 2 months- 3 months	0.73 (0.71t0 0.74)	0.56 (0.41t0 0.71)	0.59 (0.49 to 0.70)	0.32 (0.31t0 0.33)	0.36 (0.25 to 0.47)	0.88 (0.85t0 0.92)
							D2: 3 months-4 months	0.74 (0.73t0 0.76)	0.58 (0.48 to 0.68)	0.57 (0.49 to 0.65)	0.32 (0.32 to 0.33)	0.29 (0.23t0 0.35)	0.91 (0.89 to 0.92)
							D2:4 months-5 months	0.84 (0.83t00.85)	0.43 (0.36to 0.49)	0.64 (0.59 to 0.70)	0.35 (0.34 to 0.36)	0.21 (0.17 to 0.24)	0.93 (0.91t0 0.94)
							D2:5 months-6 months	0.97 (0.96 to 0.98)	0.30 (0.24 to 0.35)	0.71 (0.66 to 0.76)	0.40 (0.39 to 0.41)	0.14 (0.12 to 0.16)	0.94 (0.94 to 0.95)
							D2:>6 months	0.89 (0.87 to 0.90)	0.50 (0.43t0 0.56)	0.56 (0.51t0 0.62)	0.37 (0.36 to 0.38)	0.26 (0.23t0 0.29)	0.90 (0.89 to 0.91)
							DB:1day –7 days	0.65 (0.64 to 0.66)	0.35 (0.27t0 0.43)	0.77 (0.72 to 0.83)	0.29 (0.28 to 0.30)	0.14 (0.10 to 0.17)	0.96 (0.95 to 0.97)
							DB: 8 days–14 days	0.36 (0.36 to 0.37)	0.28 (0.21t0 0.36)	0.90 (0.87 to 0.92)	0.09 (0.09 to 0.10)	0.16 (0.12 to 0.21)	0.98 (0.98 to 0.99)
							DB: 15 days – 30 days	0.33 (0.32t0 0.33)	0.18 (0.14 t0 0.22)	0.94 (0.93t00.95)	0.04 (0.04 to 0.05)	0.16 (0.11100.21)	0.99 (0.99 to 1.00)
							DB: 1 month-2 months	0.41 (0.40t00.41)	0.16 (0.13 to 0.18)	0.94 (0.93t00.95)	0.05 (0.05 to 0.06)	0.14 (0.10t0 0.17)	0.99 (0.99 to 0.99)
							DB: 2 months – 3 months	0.42 (0.41t0 0.43)	0.18 (0.15 to 0.21)	0.92 (0.91t0 0.94)	0.06 (0.05 to 0.07)	0.10 (0.06 to 0.14)	0.99 (0.99 to 1.00)
							DB>3 months	0.50 (0.49 to 0.52)	0.14 (0.11t0 0.16)	0.93 (0.92 to 0.94)	0.06 (0.05 to 0.07)	0.10 (0.06 to 0.15)	0.99 (0.99 to 1.00)
							Naturally-acquired and	l hybrid immunity'(I	ef.: unvaccinated wit	hout prior infection	evidence)		
							Unvaccinated: NA	0.49 (0.48 to 0.50)	0.45 (0.30 to 0.60)	0.78 (0.70 to 0.85)	0.11 (0.11t0 0.12)	0.43(0.22t00.64)	0.95(0.93t00.98)
							D1 or D2: NA	0.33 (0.32 to 0.34)	0.51 (0.36 to 0.66)	0.83 (0.78 to 0.88)	0.08 (0.08 to 0.09)	0.56 (0.34 to 0.77)	0.95 (0.94 to 0.97)
							DB: NA	0.19 (0.19 to 0.20)	0.29 (0.22 to 0.36)	0.94 (0.93t00.96)	0.02 (0.02 t0 0.02)	0.29 (0.13t0 0.44)	0.99 (0.99 to 1.00)
							C:: confidence interval NA: not applicable; ⁹ Delta (respective Omi Omicron) variant [14] ⁹ Duration since receivi ⁹ Risk reductions are re ⁹ Odds ratios of sympt ⁹ rior infection. ⁹ Hazard ratios of hosp according to evidence. ¹ Naturally-acquired imm	IR: odds ratio; ref.: cron): laboratory-cc. ng the COVID-19 val lative to symptoms matic infections, a talisations after sy e of prior infection.	reference; RT-PCR: re nfIrmed (RT-PCR) SA ccine dose in questio attributable respecti ccording to the time e mptomatic infections	everse-transcription RS-CoV-2 infection v in, at presentation to vely to the Delta or t elapsed since each C i, according to the th	PCR; SARS-CoV-2: s vith mutation screen the screening cent the Omicron variant. OVID-19 vaccine do me elapsed since ea	evere acute respirate ing indicative of Del e. e reception or accor ch COVID-19 vaccine	ory coronavirus 2. ta (respective ding to evidence of dose reception or





									Omicron ^a			Deltaª	
							Immune status: time since named	Hospital admission	ICU admission	Death	Hospital admission	ICU admission	Death
							vaccine dose [®]	HR° (95%CI)	HR [.] (95%CI)	HR° (95%CI)	HR° (95%CI)	HR° (95%CI)	HR [.] (95%Cl)
							Vaccinated (ref.: unv	accinated without p	rior infection evidence	e)			
							D1: 0-28 days		1.09 (0.49 to 1.69)	1.09 (0.53t01.65)			
							D2: 0–30 days	0.72 (0.50t0 0.95)	0.54 (0.06 to 1.02)	0.71 (0.14 to 1.29)	0.40 (0.23t00.57)	0.32 (0.04 to 0.60)	0.44 (0.01t00.87)
							D2: 1–2 months	0.40 (0.27 to 0.53)	0.32 (0.06 to 0.59)	0.38 (0.10 to 0.67)	0.41 (0.25 to 0.57)	0.52 (0.21t0 0.84)	0.14 (- 0.13 to 0.42)
							D2: 2–3 months	0.56 (0.41t0 0.71)	0.22 (0.00 to 0.43)	0.12 (-0.05t00.29)	0.36 (0.25 to 0.47)	0.35 (0.16 to 0.54)	0.11 (-0.04 t0 0.26)
							D2: 3–4 months	0.58 (0.48t00.68)	0.25 (0.09 to 0.42)	0.43 (0.22 to 0.65)	0.29 (0.23t0 0.35)	0.18 (0.10t00.26)	0.31 (0.12 to 0.49)
							D2:4-5 months	0.43 (0.36 to 0.49)	0.15 (0.07 to 0.24)	0.30 (0.14 to 0.45)	0.21 (0.17 t0 0.24)	0.17 (0.12t00.23)	0.37 (0.20t0 0.53)
							D2:5-6 months	0.30 (0.24 to 0.35)				0.10 (0.07 to 0.13)	
							D2:>6 months	0.50 (0.43t00.56)		0.51 (0.36 to 0.65)		0.14 (0.11t0 0.18)	
							DB: 1-7 days		0.12 (0.02 to 0.22)		0.14 (0.10t00.17)	0.06 (0.03t0 0.10)	
							DB: 8-14 days	0.28 (0.21100.36)		0.14 (0.00t00.28)	0.16 (0.12 to 0.21)	0.07 (0.02 t0 0.12)	
							DB: 15-30 days	0.18 (0.14 to 0.22)		0.18 (0.08 to 0.28)	0.16 (0.11t0 0.21)	0.15 (0.07 to 0.23)	
							DB: 1-2 months	0.16 (0.13 to 0.18)			0.14 (0.10t00.17)	0.13 (0.07 to 0.19)	
							DB: 2-3 months	0.18 (0.15 to 0.21)	0.08 (0.04 t0 0.13)	0.14 (0.08 to 0.20)	0.10 (0.06 to 0.14)	0.08 (0.00t0 0.15)	0.09 (0.01(00.16)
							DB>3months		0.05 (0.01t00.09)			0.03 (-0.03t00.09)	0.10 (0.01t0 0.19)
							Naturally-acquired o	r hybrid immunity ^d (r	ef.: unvaccinated wit	hout prior infection	evidence)		
							Unvaccinated: NA	0.45 (0.30 to 0.60)	0.14 (-0.05 to 0.33)	0.24 (-0.09t00.58)	0.43 (0.22t00.64)	0.54 (0.10t00.97)	1.06 (0.02 to 2.10)
							D1 or D2: NA	0.51 (0.36 to 0.66)	0.42 (0.12 to 0.72)	0.34 (0.07 to 0.61)	0.56 (0.34 to 0.77)	0.39 (0.08 to 0.71)	0.90 (0.17 t01.62)
							DB: NA	0.29 (0.22 to 0.36)	0.16 (0.05 to 0.28)	0.19 (0.06 to 0.32)	0.29 (0.13 to 0.44)	0.13 (-0.05t00.30)	0.11 (-0.11 to 0.33)
159	<u>Kirsebom et al</u>	England	General population	Omicron	ChAdOx1	September 13, 2021-	TND study linki	ng adminsitra	tive databases	to assess VE a	against sympto	matic disease	
	(April 28, 2022)			Delta	Comirnaty	February 17, 2022							
					mRNA-1273								
					followed by								
					ChAdOx1								
					booster								





							Age (year) Dose	Booster	Interval	Controls Cases OR*	VE (95% CI)	
							your	Unvaccinate		[27,361 51265 Baseline	Baseline	4
								Dose 2**	n/a	175+	85175 89230 0.94)	8 (6 to 9.9)	
								Booster	Any***	0-1	11,879 7715 0.83)	20.3 (17.2 to 23.3)	
									Any***	2-6	27430 21422 0.76)	- 25.8 (23.7 to 27.8)	-
										7-13	28,809 17658 0.43)	- 58.2 (57.0 to 59.4)	-
							64		BNT162b2		0.36 (0.35-	63.8 (63.0 to	-
							40-6		BNT162b2	14-34	86719 66406 0.37) 0.43 (0.42-	64.5) 57.3 (56.4 to	-
									BNT162b2	35-69	87592 90787 0.44) 0.54 (0.52-	58.2) 46.4 (45.0 to	-
									BNT162b2	70-104	22504 29379 0.55)	47.8) 30.6 (26.8 to	_
									BNT162b2	105+	2758 4278 0.73)	34.3)	_
									ChAdOx1-S	7-13	70 40 0.59)	61.2 (40.9 to 74.6)	
									ChAdOx1-S	14-34	193 159 0.61)	51.7 (38.9 to 61.8)	
									ChAdOx1-S		216 215 0.57)	53.0 (42.6 to 61.6)	
									ChAdOx1-S			40.8 (18.6 to 56.9)	
									ChAdOx1-S			37.2 (-44.1 to 72.6)	-
								Unvaccinate		105+	1,701 2361 Baseline	Baseline	-
								Dose 2**	n/a	175+	4466 3053 0.81 (0.73-	19.5 (11.7 to 26.6)	
								Booster	Any***	0-1		34.6 (14.8 to 49.8)	
											0.71 (0.61-	- 28.6 (16.0 to 39.3)	-
									Any***	2-6		- 58.1 (51.6 to 63.8)	-
							65+		BNT162b2	7-13	0.31 (0.29-	63.8) - 68.5 (65.7 to	-
									BNT162b2	14-34	14311 3010 0.34)	71.2) 54.1 (50.5 to	-
									BNT162b2	35-69	36300 25240 0.49)	57.5) 40.1 (35.2 to	_
									BNT162b2	70-104	14210 18317 0.65)	44.5)	
									BNT162b2	105+	1970 2789 0.85)	23.1 (15.1 to 30.5)	
									ChAdOx1-S	7-13	23 8 0.83)	66.1 (16.6 to 86.3)	
								1	ChAdOx1-S	n	53 32 0.48 (0.3- 32 0.79)	51.6 (20.8 to 70.4)	
									ChAdOx1-S			44.5 (22.4 to 60.2)	-
											1.27 (0.7-	-27.2 (-131.6 to	10
									ChAdOx1-S		16 40 2.32) 0.98 (0.23 3 5 4.28)	30.1)	-
									ChAdOx1-S	105+	3 5 4.28)	N too low	
158	<u>Sheikh et al</u>	Scotland	General population	Omicron	ChAdOx1	November 1-	TNE) study li	nking ac	lminsi	trative database	s to assess	s VE against symptomatic disease.
	(April 22, 2022)				Comirnaty	December 19, 2021							
					mRNA-1273								





			the second s					S-gene-negative in	fections	S-gene-positiv	e infections	
									n Relative vaccine		tive, n Relative vaccine	
									effectiveness, % (95% CI)		effectiveness, % (95% CI)	
							16–49 years		(95%CI)		(95%CI)	-
							Unvaccinated	10 302 1003	22% (14 to 29)	14583 528	4 -98% (-109 to -87)	
							First dose					
							0-27 days	550 36	47% (24 to 63)	676 16		
							≥28 days	6570 581	30% (21 to 38)	8339 235	0 -39% (-49 to -30)	
							Second dose 0–13 days	732 46	58% (42 to 70)	805 11	9 31% (16 to 44)	
							14-69 days	732 46 4248 256	53% (42 to 70) 53% (46 to 60)	805 11 4258 26		
							70-104 days	12 581 814	33% (26 to 40)	13559 179		
							105-139 days	29209 3503	15% (9 to 21)	31963 625		
								14986 1824	3% (-5 to 11)	17991 482		
							≥175 days Third dose	13183 1435	Reference	15462 371	4 Reference	
							0-6 days	3773 515	26% (16 to 34)	4003 74	5 33% (27 to 39)	
							7–13 days	2185 143	62% (54to 68)	2155 11		
							≥14 days	12887 783	56% (51 to 60)	12798 69	4 83% (81 to 84)	
							≥50 years Unvaccinated	716 48	33% (7 to 52)	1158 49	0 -45% (-65 to -28)	
							First dose	/10 40	33 // (O 32)	1130 49	-45 m (-05 t0-28)	
							0–27 days	27 4	0 (-230 to 70)	36 1		
							≥28 days	256 13	48% (7 to 72)	343 10	0 10% (-15 to 30)	
							Second dose	23 1	62% (-207 to 95)	23	1 00% (77 - 00)	
							0-13 days 14-69 days	23 1 120 9	62% (-207 to 95) 5% (-98 to 54)	23 131 2		
							70-104 days	-	8% (-76 to 52)	149 3		
							105-139 days		35% (-10 to 62)	634 18		
							140-174 days		4% (-13 to 19)	8205 295		
							≥175 days Third dose	8007 799	Reference	10856 364	8 Reference	
							0-6 days	3522 420	0 (-15 to 13)	4352 125	0 20% (13 to 26)	
							7–13 days	3006 180	54% (46 to 62)	3146 32		
							≥14 days	17 572 1045	57% (52 to 62)	17504 97	7 88% (86 to 89)	
157	Cerqueria-Silva	Brazil	18+ year olds	Omicron	ChAdOx1	January 1-March 7.	TND stu	dy linking a	administra	tive data	bases.	
157	Cerqueria-Silva	Brazil,	18+ year olds	Omicron	ChAdOx1	January 1-March 7,	TND stu	dy linking a				
157	<u>et al</u>	Brazil, Scotland	18+ year olds	Omicron	Comirnaty	January 1-March 7, 2022			administra SARS-CoV-2 Infec			re COVID-19
157			18+ year olds	Omicron			TND stu					re COVID-19
157	<u>et al</u>		18+ year olds	Omicron	Comirnaty							re COVID-19
157	<u>et al</u>		18+ year olds	Omicron	Comirnaty		100 • 80 •					re COVID-19
157	<u>et al</u>		18+ year olds	Omicron	Comirnaty		100 • 80 •					re COVID-19
157	<u>et al</u>		18+ year olds	Omicron	Comirnaty		100 • 80 • (%) ss					re COVID-19
157	<u>et al</u>		18+ year olds	Omicron	Comirnaty		100 • 80 • (%) ss					re COVID-19
157	<u>et al</u>		18+ year olds	Omicron	Comirnaty		100 • 80 • (%) ss					re COVID-19
157	<u>et al</u>		18+ year olds	Omicron	Comirnaty		00 00 00 00 00 00 00 00 00 00 00 00 00					re COVID-19
157	<u>et al</u>		18+ year olds	Omicron	Comirnaty		00 00 00 00 00 00 00 00 00 00 00 00 00					re COVID-19
157	<u>et al</u>		18+ year olds	Omicron	Comirnaty		Vaccine Effectiveness (%)	Symptomatic 5				re COVID-19
157	<u>et al</u>		18+ year olds	Omicron	Comirnaty		00 00 00 00 00 00 00 00 00 00 00 00 00	Symptomatic 5				re COVID-19
157	<u>et al</u>		18+ year olds	Omicron	Comirnaty		Vaccine Effectiveness (%)	Symptomatic 5				re COVID-19
157	<u>et al</u>		18+ year olds	Omicron	Comirnaty		Vaccine Effectiveness (%)	Symptomatic 5				re COVID-19
157	<u>et al</u>		18+ year olds	Omicron	Comirnaty		100 80 60 40 40 40 40 40 40 40 40 40 40 40 40 40	Symptomatic 5	SARS-CoV-2 Infed	¢	Sever	re COVID-19
157	<u>et al</u>		18+ year olds	Omicron	Comirnaty		100 80 60 40 40 40 40 40 40 40 40 40 40 40 40 40	Symptomatic 1	5-8 9-12	¢	Sever	
157	<u>et al</u>		18+ year olds	Omicron	Comirnaty		100 80 60 40 40 40 40 40 40 40 40 40 40 40 40 40	Symptomatic 1	5-8 9-12	etion	Sever	
157	<u>et al</u>		18+ year olds	Omicron	Comirnaty		100 80 60 40 40 40 40 40 40 40 40 40 40 40 40 40	Symptomatic 1	5-8 9-12	etion	Sever	
	<u>et al</u> (April 14, 2022)	Scotland			Comirnaty mRNA-1273	2022	000 000 000 000 000 000 000 000	Symptomatic :	5-8 9-12 V Co	etion 2 13 Veeks since b untry Braz	0-1 2-4 005er dose 0 Scotland	5-8 9-12 213
157	et al (April 14, 2022) <u>Widdifield et al</u>		Patients with	Omicron Alpha, Delta	Comirnaty mRNA-1273	2022 March 1-November	000 000 000 000 000 000 000 000	Symptomatic :	5-8 9-12 V Co	etion 2 13 Veeks since b untry Braz	0-1 2-4 005er dose 0 Scotland	
	et al (April 14, 2022) <u>Widdifield et al</u>	Scotland			Comirnaty mRNA-1273	2022	000 000 000 000 000 000 000 000	Symptomatic :	5-8 9-12 V Co	etion 2 13 Veeks since b untry Braz	0-1 2-4 005er dose 0 Scotland	5-8 9-12 213
	<u>et al</u> (April 14, 2022)	Scotland	Patients with rheumatoid arthritis,		Comirnaty mRNA-1273	2022 March 1-November	000 000 000 000 000 000 000 000	Symptomatic :	5-8 9-12 V Co	etion 2 13 Veeks since b untry Braz	0-1 2-4 005er dose 0 Scotland	5-8 9-12 213
	et al (April 14, 2022) <u>Widdifield et al</u>	Scotland	Patients with rheumatoid arthritis, ankylosing		Comirnaty mRNA-1273	2022 March 1-November	000 000 000 000 000 000 000 000	Symptomatic :	5-8 9-12 V Co	etion 2 13 Veeks since b untry Braz	0-1 2-4 005er dose 0 Scotland	5-8 9-12 213
	et al (April 14, 2022) <u>Widdifield et al</u>	Scotland	Patients with rheumatoid arthritis, ankylosing spondylitis, psoriasis,		Comirnaty mRNA-1273	2022 March 1-November	000 000 000 000 000 000 000 000	Symptomatic :	5-8 9-12 V Co	etion 2 13 Veeks since b untry Braz	0-1 2-4 005er dose 0 Scotland	5-8 9-12 213
	et al (April 14, 2022) <u>Widdifield et al</u>	Scotland	Patients with rheumatoid arthritis, ankylosing		Comirnaty mRNA-1273	2022 March 1-November	000 000 000 000 000 000 000 000	Symptomatic :	5-8 9-12 V Co	etion 2 13 Veeks since b untry Braz	0-1 2-4 005er dose 0 Scotland	5-8 9-12 213
	et al (April 14, 2022) <u>Widdifield et al</u>	Scotland	Patients with rheumatoid arthritis, ankylosing spondylitis, psoriasis,		Comirnaty mRNA-1273	2022 March 1-November	000 000 000 000 000 000 000 000	Symptomatic :	5-8 9-12 V Co	etion 2 13 Veeks since b untry Braz	0-1 2-4 005er dose 0 Scotland	5-8 9-12 213







							$\begin{bmatrix} B \\ 100 \\ 90 \\ 90 \\ 100 \\ 90 \\ 90 \\ 10$
155	Lind et al (April 20,2022)	USA	5+ years	Omicron specifically ^	Comirnaty mRNA-1273	November 1, 2021- January 31, 2022	This TND study assessed the benefit of primary series an booster doses in the context of Omicron VOC circulation among people with and without a prior documented infection. Primary vaccination had significant but low levels of protection in people with and without prior infection which was increased by booster doses; however, the study did not find a significant increase in people with prior infection. Series the study did not find a significant increase in people with prior infection. Series the study did not find a significant increase in people with prior infection. Series the study did not find a significant increase in people with prior infection. Series the study did not find a significant increase in people with prior infection. Series the study did not find a significant increase in people with and without a prior infection. Series the study did not find a significant increase in people with and without a prior infection. Series the study did not find a significant increase in people with and without a prior infection three to the series and people with a prior infection three to the series and people with a prior infection to the series the series of the series
154	<u>Gram et al</u> (April 20,2022)	Denmark	12+ years	Alpha, Delta and Omicron [^]	Comirnaty mRNA-1273	December 27,2020- January 31,2022	This study evaluated the VE of mRNA vaccines in Denmark against infection and hospitalisation.The study reported that vaccination with mRNA vaccines was associated with protection againstinfection and hospitalizition by Alpha, Delta and Omicron VOCs.VE of 2 doses mRNA agains infection:VE 2 doses mRNA against hospitalizaton:











153	<u>Voko et al</u> (April 18,2022)	Hungary	18-100 years	Delta^	Comirnaty, mRNA-1273, ChAdOx1, Ad26.COV2.S, Sputnik,	March 4, 2020- December 31, 2021	This study assessed the effectiveness and duration of protection of six different types of vaccines with combinations as primary or booster vaccines against COVID-19 infection, hospitalization and death during a period of Delta variant predominance.
					Sinopharm		A) registered infection
							Prince prince prince prince prince prince prince based on the based on
							Automaty patternary patternary patternary patternary patternary patternary 1000 12.100 days 12.100 days 12.100 days 12.00 days 1000 1000 1000 600 600 12.100 days 12.100 days 1000 1000 1000 1000 600 600 600 1000 1000 1000 1000 1000 600 600 1000 1000 1000 1000 1000 600 1000 1000 1000 1000 1000 600 1000 1000 1000 1000 1000 600 1000 1000 1000 1000 1000 600 1000 1000 1000 1000 1000 600 1000 1000 1000 1000 1000 600 1000 1000 1000 1000 1000 600 1000 1000 1000 1000 1000 600 1000 1000 1000 1000 1000 600 1000 1000 1000 1000 1000 600 1000 1000 1000 1000 1000
152	<u>Grewal et al</u> (April 18,2022)	Canada	LTC residents aged ≥60 years	Omicron specifically^	Comirnaty, mRNA-1273		This test-negative case control study estimated the marginal effectiveness of a fourth dose of COVID-19 vaccines relative to individuals with a third dose and or unvaccinated. Figure 1: Marginal effectiveness of a fourth dose of mRNA COVID-19 vaccine against Omicron outcomes among long-term care residents in Ontario, Canada, compared to residents who received a third dose 284 days ago $u_{ij} = \frac{100}{100} = \frac{1}{100} = $





151	<u>Richardson et al</u> (April 17,2022)	Mexico	Childcare workers aged ≥18 years	Non-VOC, Alpha , Gamma and Delta^	CanSino	March 30, 2021- December 31, 2021	Prospective cohort study evaluating the VE of Cansino against laboratory-confirmed illness, hospitalisation and death associated with COVID-19. Vaccination with Cansino provided moderate protection against infection, and robust protection against hospitalization and death up to 4 months, with declines in VE seen after 120 days.
150	<u>Nasreen et al</u> (April 13,2022)	Canada	18+ year olds	Non-VOC, Alpha, Beta, Gamma, Delta^	Comirnaty mRNA-1273 ChAdOx1	December 14, 2020- September 30, 2021	Test-negative case control study conducted across 4 canadian provinces to evaluate the effectiveness of heterologous and homologous regimen of COVID-19 vaccines in preventing hospitalization or death. Figure 2: Pooled alguade vacine effectiveness agains severe outcomes of hospitalization or death for mBNA (panel A) and ChAdDx1 (panel B) vaccines in Ontario, Quebes, British Columbia, and Manitos. A roBNA vaccines B . ChAdDx1 vaccines B . ChAdDx1 vaccines D . ChadDx1 v
149	<u>Cerqueira-Silva</u> (April 13, 2022)	Brazil	18+ year olds	Omicron ^A	BNT162b2, ChAdOx1, Ad26.COV2.S and CoronaVac	January 01,2022- March 22,2022	TND and matched case-control study evaluating the impact of hybrid immunity in preventing symptomatic infection and severe disease during Omicron circulation. Prior infection with vacination provided robust protection against severe outcomes.





148	<u>Plumb et al</u> (April 15, 2022)	USA	18+ year olds	Delta→ Omicron	Comirnaty and mRNA-1273	June 20, 2021- February 24,2022	Test-negative case control study assessed effectiveness of mRNA primary series and booster vaccines in hospitalised patients with prior infection. * Among persons with a previous infection, adjusted VE <90 days after dose 1 was 42.0% (95% CI = 16.8%-59.5%) and ≥90 days after dose 1 was 42.2% (95% CI = 26.0%- 54.8%); adjusted VE <90 days after dose 2 was 44.6% (95% CI = 28.6%-56.9%) and ≥90 days after dose 2 was 39.3% (95% CI = 32.4%-45.4%); and adjusted VE <90 days after dose 3 was 67.9% (95% CI = 60.3%-74.0%) and ≥90 days after dose 3 was 62.4% (95% CI = 48.6%-72.5%).
147	<u>Kim et al</u> (April 10, 2022)	USA	18+ year olds	Delta→ Omicron	Comirnaty and mRNA-1273	October 1, 2021- February 12, 2022	$ \begin{array}{c} \hline \text{Test-negative case control study evaluating VE of 2^{nd} and 3^{rd} doses of mRNA vaccines against symptomatic infection over time across outpatient centers in 7 US states. Paper contains data stratified by prior infection, chronic conditions, and high-risk exposure. \\ \hline \\ \hline \\ \hline \\ \frac{\text{Delta}^{b}}{2\text{-Dose}} & $327/552$ (59) & 763/942$ (81) 66 (57 to 73) 63 (51 to 72) \\ 14.149 \text{ Days} & 14/239$ (6) 106/285$ (37) 89$ (81 to 94) 89 (78 to 94) \\ 2150 \text{ Days} & $313/538$ (58) 657/836$ (79) 62 (52 to 70) 58$ (44 to 68) \\ \hline \\ $
146	<u>Menni et al</u> * (April 08,2022)	UK	General population	Delta^	Comirnaty mRNA-1273 ChAdOx1	May 23, 2021- November 23, 2021	Prospective cohort study analysed sel-reported lateral flow or PCR test positivity data from an app in the UK among adults, 5-8 months after receiving primary dose and an mRNA booster. VE showed a gradual decline after the second dose.
145	<u>Glatman-</u> <u>Freedman et al</u> (March 31, 2022)	Israel	16+ year olds	Delta→ Omicron	Comirnaty	September 6, 2021- January 1, 2022	Cohort study by linking administrative databases evaluate VE of 3 rd dose versus 0 doses against infection over time. A=16-59 year olds; B=60+ year olds.








144	<u>Buchan et al</u> (April 7, 2022)	Canada	12-17 year olds	Delta→ Omicron	Comirnaty	November 22, 2021- March 6, 2022	TND conducted by linking adminsitrative databases evaluating VE against symptomatic infection and severe disease. A. Symptomatic infection B. Severe outcomes (hospitalization or death) by by b
143	<u>Fabiani et al</u> (April 6, 2022)	Italy	60+ and other priority groups (e.g. hcws)	Delta	Comirnaty mRNA-1273 ChAdOx1 Ad26.COV2.S	July 19, 2021- December 12, 2021	Cohort study among vaccine recipients comparing time intervals to day 4-10 post dose 1. Paper contains data stratified by priority groups. Any SARS-CoV-2 infection* Severe COVID-19* No. Incidenc Adjusted Cases e.per VE*(%) (95% PD PD PD PD PD PD Total 7,451 6.7 29.3 (16.3 767 0.7 59.5 (49.4 3-13 wks. after completion of primary series 26,90 3.3 67.2 (62.5 1,406 0.2 89.5 (86.1 14-18 wks. after completion of primary series 25,56 4.9 51.4 (43.6 2.0,41 0.4 82.7 (76.5 -26 wks. after completion of primary series 56,69 12.5 12.2 (-4.7) 3.912 1.1 65.3 (50.3) >-26 wks. after completion of primary series 56,69 12.5 12.2 (-4.7) 3.91
142	<u>Bansal et al</u> (April 6, 2022)	Qatar	General population	Alpha, Beta, Delta, Omicron (but no omicron specific estimate)	Comirnaty mRNA-1273 ChAdOx1 (1.6% of all vaccinated)	January 1, 2021- February 20, 2022	Matched case-control among all cases in Qatar, looking at progression to ICU. VE 89% (95% Cl, 85 to 92) between 0-4 months post the second dose. VE 91%; 95% Cl 84 to 95) between 4 -6 months after the second dose; VE 90%; 95% Cl 84 to 94)) at 6 to 9 months after the second dose.
141	<u>Florentino et al</u> (April 5, 2022)	Brazil, Scotland	12-17 year olds	Delta→ Omicron	Comirnaty	Brazil: September 8, 2021-March 8, 2022 Scotland: August 6, 2021- March 1, 2022	TND study against symptomatic and severe disease.













							73 73 74 75 75 75 65 75 54 75 40 35 30 75 10 1 Internal control (days 3-7) Week 2 Week 2 Week 3 Week 4 Week 4 Week 5 Week 6 Week 7 Week 8 (days 3-7) Time Since Dose 4
139	<u>Perumal et al</u> (April 1, 2022)	Germany	12+ year olds	Delta, Omicron	Comirnaty mRNA-1273	November 8, 2021- February 13, 2022	Analysis of surveillance data with comparison to aggregate vaccination data to calculate the VE against symptomatic disease, hospitalization, and severe disease. (Note unable to adjust for many confounders). Table 3: Effectiveness of booster vaccination against symptomatic SARS-CoV-2 infection and COVID-19-associated hospitalizations and severe illness during dominant circulation of the <u>Omicron variant</u> in Germany, CW52/2021-06/2022, by age group and time interval. Image: the transmit is the transmit
138	Ranzani et al	Brazil	18+ year olds	Delta,	Coronavac	September 6, 2021-	TND study linking adminsitrative databases. Note booster dose VE is a relative VE (compared to
	(April 1, 2022)			Omicron	Comirnaty	March 10, 2022	primary series recipients) while primary series VE is compared to unvaccianted.







						A-Vacche Effectiveness Against Symptomatic COVID-19
137 <u>Starrfelt et al</u> (March 30, 2022)	Norway	18+ year olds	Delta	Comirnaty mRNA-1273 ChAdOx1	July 15-November 30, 2021	Cohort study conducted by linking administrative databases.
136 Hansen et al (March 30, 2022)	Denmark	12+ year olds	Omicron	Comirnaty mRNA-1273	December 28, 2021- February 15, 2022	Cohort study by linking administrative databases. (first column Pfizer, second Moderna)





							a) b) b) Outcome vaccination Adjusted VK Adjusted VK Not sacinated (vel) (vel) (vel) Infection 14:30 737:0154,412.12 (vel) Infection 0:400 737:0154,412.12 (vel) Infection 0:400 737:0154,412.12 (vel) Infection 0:400 737:0154,612.12 (vel) Infection 0:400 737:0154,612.12 (vel) Infection 1:400 737:0154,612.12 (vel) Infection 1:400 stre data (vel) Infection 1:400 stre data (vel) Infection 1:400 stre data (vel) Infection againt 1:400 45:016.542.1 Infection againt 1:430 47:2103.757.91 I22+ 1:24 1:21.01 1:21.01 Infection againt 1:430 47:2103.757.91 I22+ 1:24 1:21.01 1:21.01 Infection againt 1:430
135	<u>Price et al</u> (March 30, 2022)	USA	5-18 year olds	Delta→ Omicron	Comirnaty	July 1, 2021-February 17, 2022	Protection against hangerällsnich ander 3 60x6s #3 - 00 5 - 20 9 - 12 + 20 12 +
134	- <u>Veneti et al</u> (March 25, 2022)	Norway	12-17 year olds	Delta-> Omicron	Comirnaty	August 24, 2021- January 16, 2022	Cohort study of 12-17 year olds evaluating VE against infection based on linking adminiistrative databases. Age 12-13 years 16-17 years b) Delta infections, 25 August 2021 to 16 January 2022
133	<u>Wang et al</u> (March 25, 2022)	USA	General population	Delta→ Omicron	Comirnaty mRNA-1273	October 1, 2021- January 31, 2022	TND study at Cleveland Clinic evaluating risk against infection (top table, note this can be converted to VE by subtracting the OR from 1) and death (bottom table, not this is among cases only and thus is VE against progression of infection to death).





								Patients	Positive	Odds Ratio		
							Delta Period			(95% CI)		
							Unvaccinated Dose 2	61,198	16,185 (26%)			
							≥ 180 days < 180 days Dose 3	35,931 15,028	6,737 (19%) 1,654 (11%)	0.47 (0.45 to 0.48) 0.30 (0.28 to 0.32)		
							≥ 180 days < 180 days	2,390 11,170	294 (12%) 521 (5%)	0.29 (0.26 to 0.33) 0.09 (0.08 to 0.10)		
							Other vaccination Prior infection	8,049 8,386	1,610 (20%) 565 (14%)	0.52 (0.55 to 0.59) 0.23 (0.21 to 0.25)		
							Omicron Period					
							Unvaccinated Dose 2 ≥180 days	38,858 27,318	17,614 (45%) 13,306 (49%)	0.93 (0.90 to 0.96)		
							< 180 days Dose 3	7,857	3,179 (40%)	0.74 (0.70 to 0.78)		
							≥ 180 days < 180 days	2,450 31,467	711 (29%) 7,482 (24%)	0.50 (0.45 to 0.55) 0.35 (0.34 to 0.37)		
							Other vaccination Prior infection	7,354 9,618	2,931 (40%) 3,117 (62%)	0.71 (0.67 to 0.75) 0.61 (0.58 to 0.64)		
							Variable			Delta Va Hazard Ratio		
							Vaccination s					
							Unvaccin Dose 2 ≥	nated ≥ 180 days		Referenc 0.43 (0.29 to	Reference .64) 0.43 (0.25 to 0.74)	
							Dose 2 <	180 days ≥ 180 days		0.42 (0.34 to 0.77 (0.53 to		
							Dose 3 <	180 days		0.24 (0.11 to	.54) 0.15 (0.06 to 0.40)	
132	Ng et al	Singapore	Contacts of cases	Delta	Comirnaty	March 1-August 31,	Other va		o at tran	0.87 (0.64 to smission in	.19) 0.74 (0.53 to 1.04) ouseholds of cases.	
1.02	(March 24, 2022)	Singapore	contacts of cases	Delta	mRNA-1273	2021			.5 1.	2	<u> </u>	
						-	ilisiti	accinated (ref)	zduisiti	1 - Unvaccinated	ref)	
							80 0.8 - 50 0.6 -	↓ ♦ •	.0 matic			
							10 U.4 -	$\phi \phi$	o.	₄ - ' _⊾ ↓ ♦		
									(a) ii 0.	2	(b) (c)	
							PV 0) 1 2 3 4	5	PV 0 1 2	4 5 PV 0 1 2 3 4 5	
							Mont	ths since vaccin	nation	Months since	Accination Months since vaccination	
131	Kirsebom et al	England	General population	Omicron	Comirnaty	January 17-February	TND study	<mark>/ compari</mark>	ng VE aga	inst sympto	matic disease with BA.1 vs BA.2	
	(March 24, 2022)			(BA.1 vs BA.2)	mRNA-1273	17, 2022					ase after two doses or a booster dose	
					ChAdOx1		100		areness agains	coymptonia de di		
							- 80					
							- ⁸⁰	I		٥	° [*] °*	
							00 Ctive					
							ajja 40			٩́ ا	• *	
							Vaccir	0	I			
							20		Φ ^T			
							0		25.		24 50 1014 15	
							<2			<1 1		
							● BA.1	DOGC L		Time since Vaca		
							■ DALZ			Time since vacc	a (YEWINA)	
130	Stowe et al	England	General population	Delta	Comirnaty	April 26-February 23,	TND study	/ evaluati	ng impact	of differer	case defintions on VE against severe	
	(March 24, 2022)			Omicron	mRNA-1273	2022	disease/h					
					ChAdOx1							
							0 40	2-24 Dose 2	25+	<1 1 Time since Vacc	2-4 5-9 10-14 15+ Booster	







							Figure 3. Vaccine effectiveness against hospitalizations >=2 days and >=2 days and oxygen/ventilated/on ICU using SUS by age group and manufacturer (all symptomatic controls, Omicron only) 1814
129	<u>Gazit et al</u> (March 24, 2022)	Israel	≥60 years	Omicron	Comirnaty	January 10-March 23, 2022	TND study evaluating the relative VE of the 4 th dose to the 3 rd dose against infection and hospitalizaiton/death. Figure 1. Adjusted fourth dose vaccine effectiveness against SARS-CoV-2 infection relative to three doses. Multiple tests approach.





							Figure 2. Adjusted fourth dose vaccine effectiveness against SARS-CoV-2 severe
							disease relative to three doses. Multiple tests approach.
							disease relative to unree doses. Multiple tests approach.
							7-27 28-48 49-59 Days after the 4th dose
							Dajs alien ne kurtidise
128	Horne et al	UK	General population	Alpha, Delta	Comirnaty	February 24, 2021-	Cohort study based on linking of administrative databases.
	(March 23, 2022)				ChAdOx1	December 15, 2021	Figure 2. Adjusted hazard ratios comparing BVTIS2b2 and Ch4dOx1 with unvaccinated individuals in each comparison period. Estimates for BVTIS2b2 in the 40-64 age group are omitted for all outcomes except positive SABS-GoV-2 text due to low event counts. The slopes of the dashed lines are the ratios of hazard ratios across comparison periods. Title due the research and the state of the stateo
							66 yaas 164 yaas ad 40 K4 yaan 11530 yaan 2 diricaliy uteenda
							0000-9 23 hoginalized a second
							Portuge 201
							200 Non 530 COURSE 020
							Turned to the second se
							AF4 eq (17 No) 2 Map) (19 No) (19 No) (19 Do) (29 Jul) Weeks since second does** *And not clinically vulnerable. **Alf follow-up dates are in 2021.
127	Shrothi ot al	UK	LTCF residents and	Alpha Dolta	Comirnaty	December 9, 2020	Cohort study of LTCE residents and staff VE declined from $E0.7\%$ (LE E 71.2) to 17.2% (22.0.44.6)
127	<u>Shrothi et al</u> (March 12, 2022)	UK	staff	Alpha, Delta	Comirnaty mRNA-1273 ChAdOx1	December 8, 2020- December 11, 2021	Cohort study of LTCF residents and staff. VE declined from 50·7% (15·5, 71·3) to 17·2% (-23·9, 44·6) against infection; from 85·4% (60·7, 94·.6) to 54·3% (26·2, 71·7) against hospitalisation; and from 94·4% (76·4, 98·7) to 62·8% (32·9, 79·4) against death, when comparing 2-12 weeks and \geq 12 weeks after two doses. For 19,515 staff, VE against infection declined slightly from 50·3% (32·7, 63·3) to
							42·1% 29·5, 52·4).







126	<u>Chemaitelly et al</u> (March 13, 2022)	Qatar	General population (including children)	Omicron (BA.1 and BA.2)	Comirnaty mRNA-1273	December 23, 2021- February 28, 2022	The against symptomatic and severe disease. Figure 5. Effectiveness of the BNT162b2 and mRNA-1273 vaccines against symptomatic SARS-CoV-2 BA1 Omicron infection (panels A and B, respectively) and symptomatic SARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic SARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic BARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic BARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic BARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic BARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic BARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic BARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic BARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic BARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic BARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic BARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic BARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic BARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic BARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic BARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic BARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic BARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic BARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic BARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic BARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic BARS-CoV-2 BA2 Omicron infection (panels A and B, respectively) and symptomatic BARS-CoV-2 BA2 Omicro infectively) and symptomatic BA2
125	<u>Baum et al</u> (March 13, 2022)	Finland	70+	Pre Omicron/ Omicron	Comirnaty mRNA-1273 ChAdOx1	December 27, 2020- February 19, 2022	Cohort study evaluating VE against hospitalization/ICU admission.







							Supplementary Table 11: VE against Covid-19-rolated hospital admission in 2022 Q1, Le, between January 01 and February 19. Vaccine effectiveness (in %) quantified as 1 minus the hazard ratio adjusted for age, sor., region of relatione, residence in a long-term care faelily, influenza vaccination in 2019-2020, number of nights hospitalized between 2015 and 2019 and presence of predisposing comorbidities.Cause Pysam MLE LCI UCI p-value Comirmary 12:83 6Cause Pysam MLE LCI UCI p-valueComirmary 12:83 6Comirmary 12:83 6Comirmary 12:83 6Comirmary 1:900Comirmary 1:900Spikewa: 4:900Spikewa: 4:900 <td cols<="" th=""></td>	
124	<u>Fowlkes et al</u> (March 11, 2022)	USA	5-15 year olds	Delta, Omicron	Comirnaty	July 25, 2021– February 12, 2022	Cohort study finding the adjusted VE at 14–149 days after receipt of dose 2 was 87% (95% CI = 49%–97%) against Delta infection and 59% (95% CI = 22%–79%) against Omicron infection. Adjusted VE ≥150 days after dose 2 was 60% against Delta infection and 62% against Omicron, with wide CIs that included zero.	
123	<u>Syed et al</u> (March 2, 2022)	Qatar	12+	Alpha, Beta/Gamma, Delta	Comirnaty mRNA-1273	December 16, 2020- October 31, 2021	Cohort study linking adminsitrative databases. VEs are unadjusted	





							(%) (%) (%) (%) (%) (%) (%) (%)
122	<u>Suarez Castillo et</u> <u>al</u> (March 3, 2022)	France	50+ year olds	Alpha, Beta/Gamma, Delta	Comirnaty mRNA-1273 Ad26.COV2.S ChAdOx1	January 1-December 12, 2021	TVD study/survival analysis by linking administrative databases. Figure 2 • Covid-19 vaccine effectiveness against symptomatic infections and hospitalizations among persons aged 50 years or over, according to the time elapsed since the injection of each vaccine dose, data collected from January 1 st to December 12, 2021





121	Klein et al	USA	5-17 year olds	Omicron	Comirnaty	April 2021-January	TND study evaluating VE aga	<mark>inst eme</mark>	rgency depar	tment/urge	nt care visits and hospitalizations.
	(March 1, 2022)			Delta		2022			SARS-CoV-2		
							Encounter type/Vaccination status	Total	test-positive, no. (%)	VE %* (95% CI)	
							ED or UC encounters during Delta				
							5-11 yrs	oronicroi	r predominance,	uy age group	
							Unvaccinated (Ref)	8,599	2,652 (30.8)	_	
							2 doses (14–67 days earlier) 12–15 yrs	582	124 (21.3)	46 (24-61)	
							Unvaccinated (Ref)	12,064	3,238 (26.8)	_	
							2 doses (14–149 days earlier)	4,547	254 (5.6)	83 (80-85)	
							2 doses (≥150 days earlier) 3 doses (≥7 days earlier)	1,517	378 (24.9) 3 (30)	38 (28–48) NC	
							16-17 yrs				
							Unvaccinated (Ref)	7,421	2,068 (27.9)		
							2 doses (14–149 days earlier) 2 doses (≥150 days earlier)	2,692 1,721	193 (7.2) 329 (19.1)	76 (71-80) 46 (36-54)	
							3 doses (≥7 days earlier)	64	13 (20.3)	86 (73-93)	
							ED or UC encounters, by age grou	p and pred	iominant variant	t	
							5–11 yrs** Omicron predominant ⁺⁺				
							Unvaccinated (Ref)	5,938	2,409 (40.6)	_	
							2 doses (14–67 days earlier)	486	118 (24.3)	51 (30-65)	
							12–15 yrs Deita predominant ⁺⁺				
							Unvaccinated (Ref)	9,633	1,978 (20.5)	—	
							2 doses (14–149 days earlier) 2 doses (≥150 days earlier)	4,060 798	80 (2.0) 32 (4.0)	92 (89-94) 79 (68-86)	
							Omicron predominant ⁺⁺				
							Unvaccinated (Ref)	2,336 472	1,254 (53.7)	-	
							2 doses (14–149 days earlier) 2 doses (≥150 days earlier)	719	174 (36.9) 346 (48.1)	45 (30-57) -2 (-25-17)	
							3 doses (≥7 days earlier)	10	3 (30.0)	NC	
							16–17 yrs Deita predominant ⁺⁺				
							Unvaccinated (Ref)	5,302	1,191 (22.5)	_	
							2 doses (14–149 days earlier) 2 doses (≥150 days earlier)	2,340 1,156	78 (3.3) 47 (4.1)	85 (81–89) 77 (67–84)	
							3 doses (≥7 days earlier)	2	0()	NC	
							Omicron predominant++				
							Unvaccinated (Ref) 2 doses (14–149 days earlier)	1,363 263	771 (56.6) 114 (43.4)	34 (8-53)	
							2 doses (≥150 days earlier)	565	282 (49.9)	-3 (-30-18)	
							3 doses (≥7 days earlier)	62	13 (21.0)	81 (59-91)	
							Hospitalizations during Delta or 0 5–11 yrs	micron pr	edominance, by	age group	
							Unvaccinated (Ref)	262	59 (22.5)	_	
							2 doses (14–67 days earlier)	23	2 (8.7)	74 (-35-95)	
							12–15 yrs Unvaccinated (Ref)	496	149 (30)	_	
							2 doses (14–149 days earlier)	182	7 (3.8)	92 (79-97)	
							2 doses (≥150 days earlier)	63	13 (20.6)	73 (43-88)	
							16–17 yrs Unvaccinated (Ref)	437	136 (31.1)	_	
							2 doses (14–149 days earlier)	150	7 (4.7)	94 (87-97)	
							2 doses (≥150 days earlier) 3 doses (≥7 days earlier)	82 4	14 (17.1) 1 (25.0)	88 (72–95) NC	
							a doaca (ic/ daya camici)	4	1 (23.0)		





120	Smid et al	Czech	General population	Omicron	Comirnaty	December 7, 2021-	Cohort study created by linking administrative databases. (<2 months and >=2 months prior to
	(February 25,	Republic	of country	Delta	mRNA-1273	February 13, 2022	onset)
	2022)				Ad26.COV2.S		Destaction against Delta and Omission infection
					ChAdOx1		Protection against Delta and Omicron infection
	(updated April 28, 2022)						0.9- Deta Omicron
	20, 2022)						"0.8- • • · · · · · · · · · · · · · · · · ·
							⁸ ⁸ ⁸ ⁹ ⁸ ⁹ ¹ ¹ ¹ ¹ ¹ ¹ ¹ ¹
							<u>الت</u> والتي التي التي التي التي التي التي التي
							b 0.3 i 0.4 i 0.3 i 0.3
							َةِ مَنْ عَنْ مَنْ عَنْ مَنْ عَنْ مَنْ عَنْ مَنْ عَنْ مَنْ عَنْ عَنْ مَنْ عَنْ عَنْ عَنْ عَنْ عَنْ عَنْ عَنْ ع
							Ĕ 02-
							0.1
							0.0 Inf6- Inf6+ Full2- Full2+ Booster2+
							Fig. 2. Protection provided by vaccination or previous infection against infection by
							the Omicron and Delta variants of the SARS-CoV-2 virus. Inf6-, previous infection <6 months ago; Inf6+, previous infection >6 months ago; Full2-, complete vaccination <2
							months ago; Full2+, complete vaccination >2 months ago; Booster2-, booster dose
							<2 months ago; Booster2+, booster dose >2 months ago. Shown are point estimates of protection with 95% CI.
							Table 3. Vaccine effectiveness and protection provided by post-
							infection immunity against hospitalization, for the Omicron and Delta variants of the SARS-CoV-2 virus, 95% confidence intervals (CI) in
							parentheses.
							Effect ag. Hosp. Omicron Delta Full 2- 45% (29-57%) 75% (68-80%)
							Full 2- 29% (21-37%) 79% (08-80%)
							Booster 2- 87% (84-88%) 98% (97-98%)
							Booster 2+ 79% (75-83%) 97% (95-98%)
							Table 6. Vaccine effectiveness and protection provided by post- infection immunity against hospitalization with a need for oxygen
							therapy, for the Omicron and Delta variants of the SARS-CoV-2 virus,
							95% confidence intervals (CI) in parentheses.
							Effect ag. O_2 Omicron Delta
							Full 2- 57% (32-72%) 82% (76-87%)
							Full 2+ 32% (20-43%) 82% (80-83%)
							Booster 2- 90% (87-92%) 98% (98-98%)
							Booster 2+ 85% (80-88%) 97% (95-98%)





							Effect ag. ICU Omicron Delta Full 2- 58% (3-82%) 84% (72-91%) Full 2+ 37% (12-55%) 86% (83-88%) Booster 2- 83% (75-89%) 98% (97-99%) Booster 2+ 60% (37-74%) 97% (92-99%)
119	(February 26, 2022)	Israel	16+ Maccabi insured patients	Omicron	Comirnaty	January 1-January 21, 2022	Matched TND study to evaluate relative VE against infection and hospitalization/death. All persons had received the primary series by August 1, 2021. Marginal effectiveness against infection of a booster dose given a month before the outcome period was at its peak at 59.4% (95% CI, 54.9%-63.5%). Effectiveness declined gradually with time from inoculation, reaching 16% (95% CI, 12.3%-19.5%) in those vaccinated 5 months prior to the outcome period compared to those not receiving the booster dose. As for the marginal effectiveness against severe disease, it seems that waning exists though to a much lesser degree, as effectiveness declines from 72.2% (95% CI, 37.8%-87.6%) 3 months after inoculation to 54.5% (95% CI, 13.4-76.1) five months after vaccination. However, numbers are small as also reflected by the confidence intervals.
118	Wright et al (February 25, 2022)	USA	18+ hospitalized	Pre Delta; Delta	Comirnaty mRNA-1273 Ad26.COV2.S	April 1-October 26, 2021	Case-control study of patients hospitalized in one large US network of hospitals.







117	<u>Liu et al</u> (February 18, 2022)	Australia	Persons exposed in two outbreaks (1 at a night club, 1 at a medical school graduation event)	Omicron	Comirnaty mRNA-1273 ChAdOx1	December 8, 2021- December 22, 2021	Unadjusted VE in two outbreaks by time since 2 nd dose (combined for all vaccines)TimingNight club outbreakGraduation event outbreak<1 month-33.3 (-141.4-26.3)No cases1-2 months-18.1 (-85.7-24.8)87.5 (64-95.7)2-3 months-5.9 (-67.5-33.1)60 (38-74.2)3+ months-36.2 (-114.3-13.4)32 (22-40.6)
116	<u>Wu et al</u> (February 2022)	China	18+ year old contacts of cases	Delta	Coronavac BBIBP-CorV	July 31, 2021-? (prior to November 17, 2021)	Study done in the context of an outbreak. The adjusted VE of full vaccination against symptomatic COVID-19 was 52.32% (25.73-69.39) for ≤3-month intervals and 49.95% (1.2-74.64) for 4–6-month intervals; against COVID-19 pneumonia, VEs were 60.31 (31.31-77.07) for ≤3-month and 67.08% (9.33-88.05) for 4–6-month intervals.
115	Britton et al (February 14, 2022)	USA	12+ year olds	Pre-Delta and Delta	Comirnaty mRNA-1273 Ad26.COV2.S	March 13, April 15, or June 15 (based on age-based vaccine- eligibility October 17, 2021	TND study to evaluate VE against symptomatic disease based on data collected from pharmacies (note vaccination data based on recall and some portion of 2 dose recipients received 3 doses). In the paper, there is a stratification by age group.
114	<u>Ferdinands et al</u> (February 11, 2022)	USA	18+ years	Delta, Omicron	Comirnaty mRNA-1273	August 26, 2021- January 22, 2022	TND study at 8 VISION network sites evaluating VE against emergency room/urgent care visits nad hospitalizations.







							TABLE 2. mRNA COVID-19 vaccine effectiveness* against laboratory-confirmed COVID-19-associated ¹ emergency department and un care encounters and hospitalizations among adults aged ≥18 years, by number and timing of vaccine doses ⁶ — VISION Network, 10 stat				
							August 2021–January 2022**		SARS-CoV-2 positive test result	VE fully adjusted	
							Characteristic	Total	no. (%)	% (95% Cl)*	Waning trend p value ^{††}
							ED/UC encounters Overall				
							Unvaccinated (Ref) Any mRNA vaccine, 2 doses	110,873 105,193	43,054 (39) 16,487 (16)	72 (72-73)	<0.001
							<2 mos	4,808	301 (6)	88 (87-90)	<0.001
							2–3 mos 4 mos	10,644	1,312 (12) 1,230 (12)	80 (78-81) 79 (77-80)	
							≥5 mos	79,566	13,644 (17)	69 (68-70)	
							Any mRNA vaccine, 3 doses <2 mos	25,138 15,614	2,285 (9) 920 (6)	89 (89-90) 92 (91-93)	<0.001
							2–3 mos 4 mos	8,759 736	1,120 (13) 227 (31)	86 (85-87) 75 (70-79)	
							≥5 mos	29	18 (62)	50 (-7-77)	
							Delta-predominant period Unvaccinated (Ref)	86,074	29,063 (34)	_	_
							Any mRNA vaccine, 2 doses	85,371	8,136 (10)	80 (79-81)	<0.001
							<2 mos 2–3 mos	4,253 8,662	144 (3) 527 (6)	92 (91–94) 88 (86–89)	
							4 mos ≥5 mos	8,941 63,515	721 (8) 6,744 (11)	85 (83-86) 77 (76-78)	
							Any mRNA vaccine, 3 doses	14,207	347 (2)	96 (95-96)	<0.001
							<2 mos 2–3 mos	10,621 3,542	210 (2) 134 (4)	97 (96–97) 93 (92–94)	
							>4 mos	44	3 (7)	89 (64–97)	
							Omicron-predominant period Unvaccinated (Ref)	24,799	13,991 (56)	_	_
							Any mRNA vaccine, 2 doses	19,822	8,351 (42)	41 (38-43)	<0.001
							<2 mos 2–3 mos	555 1,982	157 (28) 785 (40)	69 (62-75) 50 (45-55)	
							4 mos ≥5 mos	1,234 16,051	509 (41) 6,900 (43)	48 (41-54) 37 (34-40)	
							Any mRNA vaccine, 3 doses	10,931	1,938 (18)	83 (82-84)	<0.001
							<2 mos 2–3 mos	4,993 5,217	710 (14) 986 (19)	87 (85–88) 81 (79–82)	
							4 mos ≥5 mos	692 29	224 (32) 18 (62)	66 (59-71) 31 (-50-68)	
							Hospitalizations	29	10 (02)	31 (-00-06)	
							Overall	40.125	16,335 (41)		
							Unvaccinated (Ref) Any mRNA vaccine, 2 doses	40,125 42,326	4,294 (10)	82 (81-83)	<0.001
							<2 mos 2–3 mos	1,662 3,084	71 (4) 223 (7)	93 (91–94) 88 (86–90)	
							4 mos	3,279	234 (7)	89 (87-90)	
							Any mRNA vaccine, 3 doses	34,301 10,957	3,766 (11) 471 (4)	80 (79-81) 93 (92-94)	<0.001
							<2 mos	7,332	221 (3)	95 (94-95)	<0.001
							2–3 mos ≥4 mos	3,413 212	211 (6) 39 (18)	91 (89-92) 81 (72-87)	
							Delta-predominant period	36,214	14,445 (40)	_	_
							Any mRNA vaccine, 2 doses	38,707	3,315 (9)	85 (84-85)	<0.001
							<2 mos	1,574	49 (3) 154 (6)	94 (92-96) 91 (89-92)	
							2–3 mos 4 mos	2,790 3,129	192 (6)	90 (89-92)	
							≥5 mos Any mRNA vaccine, 3 doses	31,214 8,124	2,920 (9) 195 (2)	82 (82-83) 95 (95-96)	<0.001
							<2 mos	6,071	118 (2)	96 (95-97)	101001
							2–3 mos ≥4 mos	2,030 23	74 (4) 3 (13)	93 (91–95) 76 (14–93)	
							Omicron-predominant period Unvaccinated (Ref)	3,911	1,890 (48)	_	_
							Any mRNA vaccine, 2 doses	3,619	979 (27)	55 (50-60)	0.01
							<2 mos 2-3 mos	88 294	22 (25) 69 (23)	71 (51-83) 65 (53-74)	
							4 mos	150	42 (28)	58 (38-71)	
							≥5 mos Any mRNA vaccine, 3 doses	3,087 2,833	846 (27) 276 (10)	54 (48-59) 88 (86-90)	<0.001
							<2 mos 2–3 mos	1,261 1,383	103 (8) 137 (10)	91 (88–93) 88 (85–90)	
							2–3 mos ≥4 mos	1,383 189	137 (10) 36 (19)	88 (85–90) 78 (67–85)	
13	<u>Fabiani et al</u>	Italy	16+ years	Alpha, Delta	Comirnaty	December 27, 2020-	Cohort study of pe	ople who r	eceived at least or	ne dose of v	accine at sor
	(February 10,				mRNA-1273	November 7, 2021	Used of day 0-<14	days post d	lose 1 as proxy for	unvaccinat	ted group. Pro
											0.0.0.0.0.0.0.0
	2022)					1	and risk group in p	aper.			





							ARE-CoV2 Infection: alpha phase						
112	Butt et al (February 9, 2022)	USA	Veterans on chronic hemodialysis	Pre-Deltaà Delta	Comirnaty mRNA-1273	January 26-August 31, 2021		Infection. Test positive Vaccinated (N) 247 245 246 246 242 216 246	Unvaccinated (N) 822 822 822 822 822 822 822 822 822 82	Test negative Vaccinated (N) 112 107 85 70 74 69 54	Unvaccinated (N) 573 573 573 573 573 573 573 573 573 573	since complete VE (95% Cl) 49.1 (38.2, 58.1) 40.4 (27.8, 50.9) 23.2 (7.3, 36.4) 45.3 (33.2, 55.2) 36.8 (23.0, 48.2) 34.1 (19.0, 46.4) 42.9 (29.5, 53.8) 87.6 (76.0, 93.6)	vaccination). VE
111	<u>Risk et al</u> (February 7, 2022)	USA	18+	Pre-Deltaà Delta	Comirnaty mRNA-1273	April 1-October 20, 2021	Cohort study based on electronic medical records (note 33% of infections and 19% of hospitalizations not based on laboratory testing but based on diagnostic code, though reported sensitivity analysis showed no difference but did not provide the data).						





nfection	HR (95% CI) p-value		
•			
•			
-			
	0.13 (0.1-0.16) <0.001		
	0.28 (0.21-0.38) <0.001		
H e ri	0.36 (0.32-0.42) <0.001		
⊢ ■	0.78 (0.67-0.91) 0.002		
-	0.09 (0.06-0.13) <0.001		
H -	0.14 (0.08-0.24) <0.001		
	0.22 (0.17-0.33) <0.001		
	0.45 (0.33-0.61) <0.001		
0 0.5 1	1.5 2		
inking administrative dat	abases		
ss of CoronaVac vaccine against confirmed	Table 4 Effectiveness of CoronaVac vaccine against COVID-19		
SARS-CoV-2 infection, by length of time (in days) since two- dose vaccination or BNT162b2 booster dose, stratified by age			
	group		
ll 18-59 60-79 ≥80	Period after Overall 18-59 60-79 ≥80 vaccine (days)		
	Second dose		
43.5% 32.2% 28.3% -38.8) (42.4-44.7) (30.1-34.2) (23.4-32.9)	0-13 65.5% 79.6% 64.5% 51.4% (64.2-66.6) (77.6-81.4) (62.8-66.1) (47.3-55.1)		
56.5% 55.1% 50.3% 55.7) (55.6-57.5) (53.7-56.5) (46.8-53.6)	14-30 82.1% 91.4% 81.6% 68.7% (81.4-82.8) (90.3-92.4) (80.6-82.5) (65.9-71.2)		
52.9% 51.1% 47.0%	31-60 82.6% 89.9% 81.4% 66.5%		
52.4) (52.1-53.8) (49.7-52.4) (43.7-50.1) 48.9% 45.3% 41.0%	(82.1-83.2) (88.9-90.9) (80.6-82.2) (64.0-68.9) 61-90 80.5% 87.2% 77.6% 63.2%		
-48.3) (47.9-49.9) (43.6-46.9) (37.3-44.4)	(79.8-81.0) (86.0-88.3) (76.6-78.6) (60.4-65.8) 91-120 78.9% 89.0% 75.5% 58.0%		
46.9) (51.3-53.2) (37.8-41.8) (27.3-36.1)	(78.3-79.6) (87.8-90.0) (74.3-76.7) (54.7-61.1)		
50.6% 36.3% 22.1% (49.3-51.9) (33.8-38.7) (16.5-27.3)	121-150 77.0% 86.7% 74.9% 52.1% (76.1-77.8) (85.2-88.0) (73.5-76.3) (48.0-55.8)		
	151-180 75.0% 81.9% 74.7% 47.9% (73.9-76.0) (79.8-83.8) (72.9-76.4) (42.9-52.4)		
	>180 72.6% 74.8% 72.6% 41.4%		
39.3) (42.3-45.6) (32.2-38.2) (8.3-21.5) 6 34.1% 34.5% 10.1%	(71.0-74.2) (72.1-77.2) (69.5-75.3) (34.5-47.5) Booster (BNT162b2)		
39.3) (42.3-45.6) (32.2-38.2) (8.3-21.5) 6 34.1% 34.5% 10.1%	0-6 80.6% 89.1% 79.6% 48.8%		
39.3) (42.3-45.6) (32.2-38.2) (8.3-21.5) 6 34.1% 34.5% 10.1% 36.3) (32.2-35.9) (29.9-38.7) (1.1-18.3)	(76.4-84.0) (76.6-94.9) (73.5-84.2) (31.3-61.9) 7-13 91.4% 95.8% 88.3% 78.0%		
39.3) (42.3-45.6) (22.2-38.2) (8.3-21.5) 6 34.1% 34.5% 10.1% 36.3) (322-259) (29.9-38.7) (1.1-18.3) 5 40.3% 35.7% 11.5% 4.4.8) (31.6-47.8) (25.2-44.8) (-12.4-30.3)	(88.5-93.5) (82.9-99.0) (83.1-91.8) (67.1-85.3)		
3933) (42.3-46.6) (22.2-88.2) (83.2-15.5) 6 34.5% 34.5% 10.1% 6 34.5% (25.9-38.7) (11.1-18.3) 6 40.3% 35.7% 11.5% -44.8) (31.6-47.8) (25.2-44.8) (-12.4-30.3) 6 84.6% 75.5% 50.6% 25.90 (62.2-88.0) (64.4-97.04) (44.9-70.4)	14-30 97.3% 97.9% 97.1% 89.5%		
393) (423-45.6) (52-28.2) (83-71.5) 403 34.5% 10.1% 363) (322-35.9) (29-9-38.7) (11-18.3) 40.3% 35.7% 11.5% 40.3% 75.7% 75.9% 59.6% 84.6% 755% 59.6% 32.0% 93.2% 632-48.0) (64-8.00.8) (44-9.70.4)	(96.1-98.1) (85.0-99.7) (94.7-98.5) (83.9-93.1)		
393) (423-45.6) (52-28.2) (83-71.5) 403 445% 101% 363) (322-35.9) (29-9-38.7) (11-18.3) 40.3% 35.7% 11.5% 40.3% 25.7% 11.5% 5 4.0.3% 75% 59.6% 4250 (622-88.0) (64-68.0) (44.9-70.4) 92.3% 03.4% 32.0% 9.34% 32.0% 94.0) 007.05.5) (03.3-55) (75.0-87.0) 50.4%	(96.1-98.1) (85.0-99.7) (94.7-98.5) (83.9-93.1) >30 96.8% 100% (*) 92.0% 89.3%		
393) (423-456) (52-282) (83-215) (42) 45% (10%) (363) (322-359) (299-387) (11-18.3) (40) 40.3% 35.7% 11.5% (44.8) (316-47.8) (252-44.8) (-12.4-30.3) (48.9) (306-47.8) 750% 59.6% 82.9) (802-38.0) (69.6-80.6) (44.9-70.4) (40) 93.5% 93.4% 52.0% (40) (00.7-55.0) (03.4-55.0) (50.4-57.6)	(96.1-98.1) (85.0-99.7) (94.7-98.5) (83.9-93.1)		
3.0%	47 % 341% 34.5% 10.1% 31-36.0 (32.2-35.9) (29.9-38.7) (11-18.3) 26 40.3% 35.7% 11.5% 318-46.8 (31.6-47.8) (32.2-44.8) (-12.4-30.3) 32.% 84.6% 75.9% 59.6% 70-52.9% 80.2-88.0) (69.6-80.8) (44.9-70.4)		





							Extended Data Table 4 Vaccine eff	fectiveness against de	ath due to COVID-19 u	ising RT-PCR, by length	n of time (in days) since tw	0-	
							dose vaccination or BNT162b2 boos				·		
							Period post vaccine (days)	Overall	18-59	60-79	≥80		
							Second dose 0-13	67 MY (65 6 60 M)	00 40/ (00 5 00 4)	60 CM (67 C 74 C)	FC 0% (FA C CO O)		
							14-30			69.6% (67.6-71.6) 84.5% (83.3-85.6)			
							31-60	, ,	91.9% (89.7-93.6)		70.0% (67.2-72.5)		
							61-90		92.2% (89.8-94.0)				
							91-120	79.8% (78.7-80.8)	95.0% (93.1-96.4)	81.7% (80.3-83.0)	63.5% (59.9-66.7)		
							121-150	78.3% (77.0-79.6)	93.7% (90.9-95.7)	82.0% (80.3-83.5)	58.7% (54.3-62.7)		
							151-180	76.8% (75.1-78.4)	92.1% (88.2-94.7)	81.9% (79.7-83.8)	53.9% (48.3-58.9)		
							>180	74.8% (72.2-77.2)	90.3% (85.5-93.5)	81.5% (77.6-84.7)	45.5% (37.1-52.8)		
							Booster (BNT162b2)						
							0-6	80.3% (73.1-85.6)	100% (*)	81.4% (71.3-87.9)	59.9% (39.3-73.5)		
							7-13	92.2% (87.4–95.2)			80.7% (65.3-89.2)		
							14-30			99.1% (93.6-99.9)			
							>30	97.1% (90.5-99.1)	100% (*)	94.3% (58.3-99.2)	93.5% (73.2-98.4)		
109	Andeweg et al	Netherlands	General population	Omicron	Comirnaty	November 22, 2021-	TND study linking a	dministrativ	e databases	evaluating V	/E/risk reducti	on from prior infection	
	(February 8,			(BA.1 and	ChAdOx1	January 19, 2022	and/or vaccination.						
	2022)			BA.2)	mRNA-1273		A. Delta-Omicron BA.1 col	hort	Variant Omicron E	W.1 Delta			
	(updated May			Delta	Ad26.COV2.S		Previous infection,	Primary vaccination	Boost	w			
	12, 2022)												
							90 80 70 60	******					
								1 + + + + + +					
							69-20						
							First start primary vaccination, then infection	First infection, then primary vaccination		fection, er			
								1	• •				
									+ 1				
							30 20						
							-10						
							and the second s	ବ୍ ବ ବ୍ ବ୍ ବ୍ ବ୍ ବ୍ ବ୍ ବ୍ ବ୍	A 2 2 2 3 3 4	202,10°			
								ి లి లై లై లై లై Time since last event (r		5° 0°			
							B. Omicron BA.1-BA.2 coh		nt Omicron BA.1 -	- Onices BA 2			
							Previous infection,	Primary vaccination	Boost				
							unvaccinated	+					
							80 70 60	12,					
							70 60 50 40 30	1 94444					
							20 10 20						
							6 -20						
							First start primary vaccination, then infection	First infection, then primary vaccination	Previous in boost	fection, er			
								49444	1				
							67 70 60 50	⊺ `* ?∤ <u>∤</u> }					
							40 30 20						
							10 0 -10						
							· · · · · · · · · · · · · · · · · · ·	999330	1 2983.24	20° N			
							and B. B. B. C. B. C. B. C.	ົອີອີອູຊູຊູຊູຊູ Time since last event (r	04	04 ⁶			
								Little Since sits event (212.1				
													_





108	Chemaitelly et al	Qatar	General population	Omicron	Comirnaty	December 23, 2021-	Matched TND study based on linking adminsitrative databases.
108	Chemaitelly et al (February 8, 2022)	Qatar	General population	Omicron	Comirnaty mRNA-1273	December 23, 2021- February 2, 2022	Matched TND study based on linking administrative databases. Figure 1. Effectiveness of the BNT162b2 vaccine against A) symptomatic SARS-CoV-2 Omicron infection and B) severe, critical, or fatal COVID-19 due to Omicron infection. C) Effectiveness of the mRNA-1273 vaccine against symptomatic SARS-CoV-2 Omicron infection. Data are presented as effectiveness point estimates. Error bars indicate the corresponding 95% confidence intervals.
							The line arcs woodstation data was were done to maximize statistical precision in each analysis as the purpose of the BATTER22 and miRMA-1272 statistical and was very cortical, or failed COVID-16.
							$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$
107	Lauring et al (February 7, 2022)	USA	≥18 years	Delta (for the duration analysis	Comirnaty mRNA-1273	July 4-December 25, 2021 (for the Delta analysis)	TND case control study in 21 hospitals in the US (IVY Network). For Delta, VE against hospitalization 88% (95% CI: 86 to 90%) 14-150 days post 2 nd dose; >150 days, VE was 81% (78 to 84%).





CEPI

	(updated March 9, 2022)						
106	<u>Kislaya et al</u> (January 31, 2022)	Portugal	≥12 years	Deltaà Omicron	Comirnaty ChAdOx1 mRNA-1273 Ad26.COV2.S	December 6-21, 2021	Compared the odds of vaccination in Delta versus Omicron cases. (higher odds =lower VE of Omicron). Omicron). Complete primary vaccination <113 days
105	Corrao et al (January 27, 2022)	Italy	≥12 years	AlphaàDelta	Comirnaty ChAdOx1 mRNA-1273 Ad26.COV2.S	January 17-October 20, 2021	<section-header><section-header><figure><text><text><text><text><text></text></text></text></text></text></figure></section-header></section-header>





101					a · ·		
104	Roberts et al	USA	Adults	Multiple	Comirnaty	January 1-December	TND study evaluating VE against infection (top) and hospitaliation/death (bottom). Note that this is
	(January 31,				mRNA-1273	31, 2021	a combination of primary and booster dose VE in quarter 4.
	2022)				(for duration)		Vaccination Orwaral 01 02 03 04
							Ang (m)
							<3 Montes
							Naccine so eo 75 eo eo 105 eo eo 10
							• Moderna ve (ciliens) ve (ciliens) ve (ciliens) ve (ciliens) ve (ciliens)
							B VE for Severity
							D VETOT Sevenity Vaccination Overall 01 02 03 04
							^** · · · · · · · · · · · · · · · · · ·
							<3 Judits
							>> 3 Monta
							• Hodema VE (CI 69%)
103	<u>Belayachi et al</u>	Morocco	≥18 year olds	Unknownàdel	BBIBP-CorV	February 1-October	TND linking adminsitrative databases to evaluate VE against severe disease. As a function of time
	(January 27,			ta		1, 20221	after vaccination of second dose vaccination, vaccine effectiveness among persons who had
	2022)						received the second dose 1–30 days earlier was 88% (95% Cl, 84-91), 87% (95% Cl: 83-90) among
							those who had received it 31–90 days earlier, 75% (95% CI: 67-80) among those who had received
							it 91–120 days earlier, 61% (95% CI: 54-67) among those who had received it 121–150 days earlier,
							64% (95% CI: 59-69) among those who had received it \geq 150 days earlier.
							Note they attempted to stratify by age (>/< 60 years) showing a trend towards a lower VE gainst
100					a		severe/critical disease in those over 60 but confidence intervals were overlapping.
102	Lytras et al	Greece	≥15 year olds	Alphaà Delta	Comirnaty	January-December	Cohort study linking administrative databases evaluating VE against intubation and death. VE
	(January 29,				ChAdOx1	2021	provided for 6 months
	2022)				mRNA-1273		
					Ad26.COV2.S		





							Vaccine		VE (%)		VE (%)	
							3-dose BNT162b2 (age 15-79)	•	98.2 (97.2-98.9)	-	98.3 (96.8-99.1)	
							3-dose BNT162b2 (age 80+)	•	97.5 (95.5–98.6)	•	98.4 (97.4-99.0)	
							2-dose BNT162b2 (age 15-59)		98.1 (97.5–98.6)	-	96.5 (94.8-97.6)	
							2-dose BNT162b2 (age 60-79)	-	96.7 (95.9–97.4)	-	94.1 (92.7-95.2)	
							2-dose BNT162b2 (age 80+)	•	94.2 (92.0-95.7)	•	91.0 (88.4–93.0)	
							2-dose BNT162b2 (age 15-59, at 6 months)	•	95.5 (94.3-96.5)	-	93.8 (91.0-95.7)	
							2-dose BNT162b2 (age 60-79, at 6 months)	•	92.0 (91.0-92.9)	•	89.4 (87.9-90.8)	
							2-dose BNT162b2 (age so+, at 6 months)	•	85.9 (83.5-88.0)	•	84.0 (82.2-85.6)	
							2-dose mRNA-1273 (age 60-79)		98.9 (97.3-99.5)		98.4 (95.5-99.5)	
							2-dose mRNA-1273 (age 80+) 2-dose mRNA-1273 (age 60-79, at 6 months)	-	97.9 (90.2-99.5) 95.1 (93.0-96.5)		96.7 (87.9-99.1) 96.2 (93.6-97.7)	
							2-dose mRNA-1273 (age 80-79, at 6 months) 2-dose mRNA-1273 (age 80+, at 6 months)		90.6 (67.0-97.3)	_	96.2 (95.8-97.7) 92.0 (80.0-96.8)	
							2-dose ThRNA-12/3 (age 80*, at 6 months) 2-dose ChAdOx1 nCoV-19 (age 60-79)		97.2 (95.3-98.3)		95.4 (91.2-97.6)	
							2-dose Chadox1 nCoV-19 (age 80+3) 2-dose Chadox1 nCoV-19 (age 80+3)		97.8 (91.7-99.4)	-	92.6 (84.2-96.5)	
							2-dose ChadOx1 nCoV-19 (age 60-79, at 6 months)		90.3 (87.4-92.5)	-	89.8 (85.2-93.0)	
							2-dose ChAdOx1 nCoV-19 (age 80+, at 6 months)		92.4 (72.7-97.9)		83.4 (69.6-90.9)	
							1-dose Ad26.COV2.S (age 15-59)		85.0 (73.9-91.4)	-	81.7 (57.5-92.1)	
							1-dose Ad26.COV2.S (age 60-79)		79.6 (65.2-88.0)	_ _	69.1 (43.2-83.2)	
							1-dose Ad26.COV2.S (age 80+)		85.0 (62.3-94.0)		61.9 (43.2-74.4)	
							1-dose Ad26.COV2.S (age 80+, at 6 months)		91.7 (75.5-97.2)		80.6 (59.7-90.7)	
							1-dose BNT162b2 (age so+)	e	56.0 (37.7-69.0)		68.7 (54.9-78.3)	
								20 40 60 80 1	1 00 2	0 40 60 80 10	0	
								VE (%) against		VE (%) against		
								Intubation		death		
101	Goldhaber-	USA	Prison population	Delta	Comirnaty	June 1-November 5.	Matched TND among case	os ovaluating	duration of	nrotection	against infection	of early vs late fully
101		UJA		Delta	,		•			•	•	
	Fiebert et al		and staff		mRNA-1273	2021	(primary series) vaccinate	•	•			
	(January 23,						[OR], 1.25; 95% Confiden	ce Interval [CI], 1.13 – 1.4	40) in each 2	8-day period pos [.]	t-vaccination;
	2022)						among residents, the odd	ls increased b	v 21% (OR,	1.21; 95%CI	1.08 – 1.36) (Figu	ure 1). Compared
	· ·						with individuals within 60				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	<i>'</i>
							greater ≥181 days since f		•		oci 1.92 – 9.89) a	nu nearly threefold
							greater for residents (OR,	2.89; 95%CI	1.40 – 5.98			
100	Bedston et al	Wales	Healthcare Workers	AlphaàDelta	Comirnaty	December 7, 2020-	Cohort study. 2 weeks aft	er dose 2, VE	against infe	ection was 6	7% (aHR 0.33, 95	%CI 0.24–0.44).
1	(January 20,					September 30, 2021	This increased in weeks 2	–5 to 86% (aF	IR 0.14.95	%CI 0.09–0.2	1). and decrease	d to 77% over
1							weeks 6–13. After this, va	•	-			
	2022)											een weeks 14–25,
							and from week 26 vaccine				,	
<u>99</u>	Accorsi et al	USA	≥18 year olds	Deltaà	Comirnaty	December 10-	TND study in ICATT (free	testing sites t	nroughout	US) against s	ymptomatic dise	ase. Note OR can be
	(January 21,			Omicron	mRNA-1273	January 1, 2022	converted to VE by the fo	rmulate VF=1	-OR			
						Junuary 1, 2022		alute vL=1				
	2022)											





							Figure 2. Odds Ratios for the Association of 2 Doses of mRNA Vaccine by Months Since Second Dose and Symptomatic SARS-CoV-2 Infection Gaused by the Omicron or Delta Variants Among Adults 18 Years or Older Tested in the increasing Community Access to Testing Platform, December 10, 2021, to January 1, 2022
							0 1 2 1 4 5 7 6 10 11 Months since second vacche dose Sample size, including 2 doses and unvacched Sample size, including 2 doses and unvacched 17320 18017 18703 19683 19884 19661 21533 27146 27795 20747 19202 17910 Image: Imag
							C 2 Does of mRNA-1273 vaccine
							0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
98	Thompson et al (January 21, 2022)	USA	≥18 year olds	Deltaà Omicron	Comirnaty mRNA-1273	August 26, 2021- January 5, 2022	TND study in VISION network calculating VE against emergency department/urgent care visits and and hospitalizaiton among persons with symptoms consistent with COVID-19





							TABLE 2. mRNA COVID-19 vaccine effectiveness* against laborato encounters and hospitalizations among adults aged ≥18 years, VISION Network, 10 states, August 2021–January 2022 [®]			
							Encounter/Predominant variant period/Vaccination status	Total	SARS-CoV-2 positive test result, no. (%)	VE, %* (95% CI)
							D or UC encounters Dehts predeminant Unscicitatel (fief) Any mR4A vacine 2 doses (14–179 days earlier) 2 doses (14) doys earlier) 2 doses (14) doys earlier) 2 doses (14) doys earlier(14) 2 doses (14) dogs earlier(14)	98,087 39,629 52,596 14,523 6,996 1,746 3,876 3,876 3,876 3,876 3,876 3,6180 8,092 460	no. (%) 36.542 (37.2) 3.209 (8.3) 6.033 (8.3) 4.09 (3.2) 3.398 (46.6) 591 (3.3) 2.02 (7.7) 5.20 (13.4) 14.272 (38.2) 055 (6.1) 2.553 (6.8) 209 (2.6) 174 (37.8) 14.22	%* (95% C) = 96 (52–57) 76 (72–77) 76 (73–74) 94 (93–94) 13 (12–41) 82 (75–84) 14 (93–94) 16 (90–92) 94 (93–92) 16 (95–90) 16 (95–90) 16 (95–90)
97	<u>Tartof et al</u> (January 19,	USA	≥18 year olds enrolled in Kaiser	Delta Omicron	Comirnaty	December 1, 2021- February 6, 2022	TND study of persons admitted t COVID-19.	o the eme	86 (17.6) 24 (4.7)	57 (39–70) 90 (80–94)
	2022) (updated April 22, 2022)		insurance				Hospital advisions due to delta (D. 16.17.27) variant Second door Delta door D	Hospital admission due to Second d	one Third down	
							Second does There does not a second does the s	Second d		
96	Amodio et al (January 19, 2022)	Italy	≥18 year olds	AlphaàDelta	Comirnaty mRNA-1273	January 1-September 30, 2021	Cohort study of 3.9 millions adul trends for vaccine effectiveness, significant for all the three evalu infection; -2·27% per month, p=(COVID-19 intubation/death, resp	measured ated outco)·029 agair	as monthly perce omes (-4·76% per i	ntage chan month, p<0





							Figure 4: Vaccine effectiveness estimates after adjustment for age and sex according to the different assessed outcomes and follow-up periods. A vaccine effectiveness againt 5AB5-CoV-2 infection Manual Source of the S	
							July September (3) 15 90042.6 670 308642.7	
95	Suah et al (January 16, 2022)	Malaysia	General population	Delta	Comirnaty CoronaVac	September 1-30, 2021	Compared early (April-June) vs late (July-August) vaccinated persons (comparing to unvaccin based on census data). For BNT162b2, crude vaccine effectiveness against COVID-19 infecti declined from 90.8% (95% CI 89.4, 92.0) in the late group to 79.1% (95% CI 75.8, 81.9) in the group. Vaccine effectiveness for BNT162b2 against ICU admission and deaths were compare between the two different periods. For CoronaVac, crude vaccine effectiveness waned again COVID-19 infections from 74.4% in the late group (95% CI 209 70.4, 77.8) to 30.0% (95% CI 18.4, 39.9) in the early group. It also declined significantly against ICU admission, dropping f 56.1% (95% CI 51.4, 60.2) to 29.9% (95% CI 13.9, 43.0) (adjusted). For deaths, however, CoronaVac's effectiveness did not wane after three to five months of full vaccination. Wanin more prominent in 60+.	ions e late able inst from
94	<u>Chiew et al</u> (January 8, 2022)	Singapore	12-18 year olds	Delta	Comirnaty	June 1-November 20, 2021	Cohort study evaluating VE against infection and disease.	





93	UKHSA	UK	Delta,	Comirnaty	November 27- April,	Figure 1. Vaccine effectiveness over time from completion of second dose.
3	(April 28, 2022) Update of #83/Dec 31 st analysis (Note <u>Andrews</u> <u>et al</u> published March 2 with data through mid-January in case you're interested in the methods).		Omicron	ChAdOx1 mRNA-1273	2021	Ve tagainst symptomatic disease Two doses of ChAdOx1-S with a BNT162b2 or mRNA-1273 booster dose Two doses of ChAdOx1-S with a BNT162b2 or mRNA-1273 booster dose Two doses of BNT162b2 with a BNT162b2 booster Time since Vaccine (weeks) Dose 2 BNT162b2 conter Time since Vaccine (weeks) Dose 2 BNT162b2 booster Time since Vaccine (weeks)







	Two doses	of mRNA-1273 with a BNT1	62b2 or mRNA-1273 boost	er dose	
100	-			1	
80	0	T T			
<u>8</u> 60	0	. 0 0		° • 1	
40	0	-	0	o ¢	
20		0 0 0			
o se el					
-20					
-40					
-60					
	2-4 5-9 10-14	15-19 20-24 25+ 1 2-4	5-9 10-14 15-19 1	2-4 5-9 10-14 15-19	
	Dos	se 2 BN	162b2 booster	mRNA-1273 booster	
© Omicro ■ Delta	n	Time	since Vaccine (weeks)		
Combi	inad for $\mathbf{A7}$	Dizor Modorno I	vegeines: VE egeir	at hospitalization	with different defintions)
			accilies. VE again		with different definitions)
			SUS at least 2 days	SUS at least 2 days and either oxygen,	
		ECDS symptomatic	with ARI code in	ventilation or ICU	
		with onset date	primary field	with ARI code in	
				primary field	
		18 t			
	Interval	VE	VE	VE	
Dose		48.5 (12.3 to 69.7)	36.2 (-33.9 to 69.6)		
	28+	48.7 (32.8 to 60.8)	44.1 (25.6 to 58)	75 (42.4 to 89.1)	
Dose 2	2 0 to 13	39.6 (-31.5 to 72.2)	88.9 (58.4 to 97)		
	14 to 174	54.7 (45.3 to 62.4)	69 (58.1 to 77)	86.7 (63.6 to 95.1)	
	175+	34.6 (21.7 to 45.4)	56.1 (46.4 to 64)	82.3 (67.7 to 90.3)	
Booste		63.9 (52.2 to 72.8)	74.3 (55.9 to 85)	90.7 (56 to 98.1)	
	7 to 13	80.1 (73.5 to 85.1)	90.9 (83.2 to 95.1)	07.4 (00.04) 00.01	
	14 to 34	82.4 (78.6 to 85.6)	88.6 (84.9 to 91.5)	97.1 (92.2 to 98.9)	
	35 to 69 70 to 104	72.7 (67.2 to 77.2) 66.9 (59.1 to 73.3)	85.8 (82.4 to 88.5) 80.2 (74.9 to 84.4)	94.3 (88.9 to 97.1) 89.9 (78.3 to 95.3)	
	105+				
	100+	53.6 (36.9 to 65.9)	67.4 (53.1 to 77.4)	75.9 (15.8 to 93.1)	
	Interval	VE	VE	VE	
Dose		12	43.9 (-41 to 77.7)	16	
Dose	28+		43.9 (-41 to 77.7) 53.4 (36.3 to 65.9)	78.3 (43.7 to 91.7)	
Dose 2	_		53.4 (56.5 to 66.5)	10.0 (40.1 10 01.1)	
Dose	14 to 174	77.8 (45 to 91)	82.3 (74.3 to 87.8)	90.9 (72.6 to 97)	
	175+	66.7 (43.4 to 80.4)	57.7 (49.6 to 64.4)	73.4 (55.1 to 84.3)	
Booste		85.8 (61.5 to 94.7)	77.9 (65.3 to 85.9)	89.2 (63.1 to 96.8)	
Boose	7 to 13	92.3 (76.3 to 97.5)	84.7 (76 to 90.2)	94.7 (71.6 to 99)	
	14 to 34	92.4 (86 to 95.8)	91.3 (89.1 to 93.1)	95.8 (91.3 to 97.9)	
	35 to 69	87 (79.2 to 91.8)	89.3 (87.3 to 90.9)	92.8 (88.4 to 95.6)	
	70 to 104	84 (74.6 to 89.9)	88.1 (86.1 to 89.9)	92.5 (88.1 to 95.2)	
	105+	76.9 (60.6 to 86.4)	85.3 (82.4 to 87.6)	86.8 (77.1 to 92.3)	
5005-5		Select this sectors is during		COURD 40 testula	
Combi	ined for AZ	, Pfizer, Moderna v	accines: VE accir	et mortality	
Collid	med for AZ	, i fizer, wiouerna v	accines. v E agan	ist mortanty	







									,			
							Dose	Interval after dose	Odds Ratio	VE (95%	CI)	
							2	25+ weeks	0.52 (0.34-0.81)	47.9 (19.3	to 66.4)	
							3	2-4 weeks	0.06 (0.03-0.12)	93.6 (88	to 96.6)	
							3	5-9 weeks	0.11 (0.07-0.17)	88.9 (83.4	to 92.6)	
							3	10+ weeks	0.12 (0.09-0.18)	87.6 (81.9	to 91.5)	
92	Tseng et al*	USA	18+ year olds	Delta,	mRNA-1273	December 6-23, 2021	TND case	<mark>e control stu</mark>	dy done by linking a			
	(February 21,		enrolled in Kaiser	Omicron					Delta V	E (95% CI) 🛛 OI	micron VE (95% CI	
	2022)		insurance					st Infection	(-		(2.2.1)	
							2 dose (14-90				(0-3.1) 0.4 (5-49)	
	[update from						91-180		•		.2 (0-30.7)	
	January 21							0 days			(0-1.2)	
	preprint]						>270 (,			(0-1.7)	
							3 dose	,			2.5 (56.2-67.9)	
							3rd d	ose on or after	10/21 95.7 (94	1.2-96.9) 63	3.6 (57.4-68.9)	
							3rd d	ose prior to 10/2	21 90.7 (81	.4-95.3) 39	9.1 (3.8-61.5)	
							3 dose	(immunocomp	petent) 95.7 (94	1.2-96.8) 63	3.6 (57.4-68.9)	
								lose on or after		,	4.1 (57.9-69.4)	
							3 rd C	lose prior to 10/	21 93.1 (83	.9-97) 49	9.0 (12.6-70.2)	
91	Grgič Vitek et al	Slovenia	18+ year olds	Delta	Comirnaty	October 2021				ses specifical	lly evaluated VI	E against SARI hospitalization.
	(January 6, 2022)				mRNA-1273		Note res	ults are una	djusted.			
								Ful	Vaccine effectiveness			
							Age group (% 95% CI			
							Vaccinated	3 months ago				
							18-49		97 90-99			
							50-64		94 91-97			
							≥ 65		93 88-96			
							vaccinated A	4–5 months ago	NA NA			
							50-64		90 79-95			
							≥ 65		85 81-88			
							Vaccinated ≥ 18−49	6 months ago	23 0-69			
							50-64		89 56-97			
							≥ 65		43 30-54			
90	Zheutlin et al	USA	18+ year olds who	Alpha, Delta,	Comirnaty	January 1-September	Matcheo	l case contro	ol using an administr	ative dataset	among vaccina	ated persons, comparing the
	(January 6, 2022)		had been fully	nonVOC	mRNA-1273	7, 2021	odds of i	nfection, ho	spitalization, and ICI	J admission a	t 28 day interv	als post dose 2 relative to the
			vaccinated		Ad26.COV2.S		1 st mont	h after full v	accination. Note out	comes define	ed by COVID-19	ICD10 codes or SARS-CoV-2
							PCR test	ing.				







							Figure 2. Odds ratios (OR) and 95% CI assessing durability of baseline vaccine protection against COVID-19 breakthrough infections, hospitalizations, and ICU admissions. a) Ad26.COV2.S Ad26.COV2.S Infection Reference) Month 3 Month 4 1,16 1,17 Month 4 1,18 1,16 1,19 0,89 1,16 1,11 1,12 0,89 1,12 0,89 1,12 1,2 0,89 1,12 1,2 0,89 1,2 0,89 1,2 0,89 1,2 0,89 1,2 0,89 1,2 0,89 1,2 0,89 1,2 0,89 1,2 0,89 1,2 0,89 1,2 0,89 1,2 0,89 0,2 4 6 0 0,2 4 6 0 0,73 1,36
89	Lyngse et al (January 6, 2022)	Denmark	General population	Delta	Comirnaty ChAdOx1	June 21-October 26, 2021	$\frac{Month 5}{Month 6} + \frac{2.37}{OR} + \frac{3.54}{OR} + 3.54$
88	(January 5, 2022)	Israel	12-16 year olds enrolled in Maccabi health services	Delta	Comirnaty	June 15-December 8, 2021	14-41), respectively, between time points corresponding to 0-1 months and 7-8 months after vaccination Matched case control evaluating association between time since vaccination and infection (red) and disease (blue). Image: the state of the state







87	Fisman et al (January 5, 2022)	Canada	5+ year olds	Alpha, Beta, Gamma, Delta, nonVOCs	Comirnaty ChAdOx1 mRNA-1273 (homologous	December 2020- October 2021	Case-Cohort study looking at VE against infection combined across the different platforms over time since vaccination as well as evaluated impact of dosing intervals.
					and heterologous)		0.375 • • • • • • • • • • • • • • • • • • •
86	Buchan et al (January 28, 2022) [updated from January 1, 2022 version]	Canada	18+ year olds	Delta, Omicron	Comirnaty ChAdOx1 mRNA-1273 (vaccinated persons had at least 1 dose of an mrna vaccine)	December 6- December 26, 2021	
85	<u>Cerqueria-Silva</u> <u>et al</u> (December 27, 2021)	Brazil	18+ year olds with prior infection 90+ days prior to testing in study period	Gamma, Delta	Coronavac, Comirnaty ChAdOx1 Ad26.COV2.S	January 18, 2021, - November 11, 2021.	Matched TND study linking adminsitrative databases. VE against symptomatic disease on top; severe disease on bottom.





							BNT162b2 ChAdOx1 CoronaVac Ad26.COV2.S Table A4. Vaccine BNT162b2	Va	>90 days 100% (*) 56.8% (46.6-65.1) 38.0% (33.1-42.5) 30.6% (-12.4-57.1) 214 days after so ccine waning r series complet >90 days 100% (*) 95.1%	tion) p-value 0.765	
84	Hitchings et al (December 24, 2021)	Brazil	18+ year olds living in Sao Paulo	Gamma, Delta	Coronavac	January 17- September 30, 2021	period day 14- OR for sympto	(77.6-92.0) 86.6% (79.8-90.3) 60.2% (-10.8-85.7) linking adm 41 post dos	(84.8-98.4) 74.4% (63.3-82.2) 41.0% (-240.9-89.9) hinsitrative Se 2).	-7	s among persons with 2 doses of coronavac (ref
									± ± €	4,054 66,79	Priority status ● Non-HCW ▲ HCW
							8 2 0.5 0.12	1 42-69 70-97 Days since s	H H H	181 ≥ 182	







				OR against hospitalization or death
83 <u>UK HSA</u> (December 24, 2021) (update of <u>Andrews et al</u> publication)	UK General population	Delta, Comirnaty Omicron ChAdOx1 mRNA-1273	November 27- December 17, 2021	Two doses of ChAdOx1-S with a BNT162b2 or mRNA-1273 booster dose Image: Colspan="2">Image: Colspan="2" Image: Cols





							mRNA-1273
82	Tabak et al (December 22, 2021)	USA	18+ year olds	NonVOC, Alpha, Delta	Comirnaty mRNA-1273 Ad26.COV2.S	May 1-August 7, 2021	TND study on patients presenting to CVS with symptoms for testing. (final dose in primary series)
81	<u>Kissling et al</u> (December 22, 2021)	8 European countries	30+ years	Delta	Comirnaty mRNA-1273 ChAdOx1 Ad26.COV2.S	July-August 2021	TND study in primary care sites evaluating VE against symptomatic disease







							Table 3: Effectiveness of complete COVID-19 vaccination among participants in the primary care and community I-MOVE-COVID-19 and ECDC VE study, by time since vaccination and vaccine product, Europe, July–August 2021					
							Analysis by time since vaccination					
							Brand, age group and time	Cases / controls	Crude VE (95% CI)*	Adjusted VE (95% CI) ^b		
							since vaccination					
							Comirnaty, age 30–59 years	1	1	1		
							Unvaccinated Vaccinated 14–29 days	1045/1684				
							Vaccinated 30–59 days	123/1287	87 (84-89)	87 (83–89)		
							Vaccinated 60–89 days	261/1584	75 (71–79)	76 (72-81)		
							Vaccinated ≥90 days	60/335	70 (59–78)	72 (61-80)		
								151/647	66 (58–72)	65 (56-71)		
							Comirnaty, age 60+ years ^c Unvaccinated					
							Vaccinated 14–29 days	74/161				
							Vaccinated 30–59 days	2/30	-	-		
							Vaccinated 50–59 days	32/425	67 (42-81)	65 (37-80)		
							Vaccinated 60–89 days	146/951	65 (49–76)	66 (48-78)		
							Vaccinated 290 days	192/1159	66 (51-76)	64 (44–77)		
							years ^d					
							Unvaccinated	990/1655				
							Vaccinated 14-29 days	21/107	71 (52-83)	72 (52-83)		
							Vaccinated 30–59 days	79/320	67 (56-75)	67 (57–75)		
							Vaccinated 60–89 days	42/162	64 (47-76)	65 (48-76)		
							Vaccinated ≥90 days	9/50	-	-		
							Spikevax, age 30–59 years*					
							Unvaccinated	1033/1672				
							Vaccinated 14–29 days	2/180	98 (92-100)	98 (93-100)		
							Vaccinated 30-59 days	19/285	91 (85–94)	91 (85–95)		
							Vaccinated 60-89 days	6/98	89 (75-96)	90 (76-96)		
							Vaccinated ≥90 days	11/33	-	-		
							Janssen, age 30–59 years ^r	,				
							Unvaccinated	919/1578				
							Vaccinated 14–29 days	19/61	-	-		
							Vaccinated 30–59 days	123/338	46 (32-57)	50 (36-62)		
							Vaccinated 60–89 days	70/205	45 (26-60)	52 (33-66)		
							Vaccinated ≥90 days	5/17	-	-		
30	<u>Tartof et al</u> (December 21, 2021)	USA	3 million Kaiser Permanente members, 18+ years	Non-VOC, Alpha, Delta,	Comirnaty	December 14, 2020- December 5, 2021	Cohort study looking stratification by age g though immunocomp significant.	group and imm	unocompromised	status, with simi		
	(updated February 14, 2022)											







							A 300 9 0 10 0
							10 C. Honorth I. Bu-C. Timo 2. Do-C. Timo 3. Bo-Vitano 4. Bu-C. Sino 5. Stor-Skimo 6. Bu-C. Timo 7. Titled dues of The skine molecular of BRITISIOS 2 Also 2. Store 1. Build dues of BRITISIOS 2 Also 2. Store 1. Store
							B *** • • ** • ** • ** • ** • *** • ***
							Adduced Vectors of Medical Address of Medical Addre
							20 50 6 ct month 1 to c2 mo 2 to c3 mo 3 to c4 mo 4 to c5 mo 5 to c4 mo 5 to c4 mo 327 mo 12 and Amor Test Abour of MITISTA 2 Amo Test Abour of Abour o
							Processor BCAB EQ.241 20,041 20,041 20,041 20,047 20,247 50,245 50,256 50,278 20,044 Figure 1. Vaccine effectiveness of 2- and 3-doses of BVT162b2 against (A) SARS-CeV-2 Infections and (B) COMD-19 hospital admis- sions - December 14, 20,201 to December 5, 2021. "Blue dicker represent 2-dose VC estimates, and the yellow dicker represent 3-dose VC estimates. The bars represent 99% confi- dence intervals. Estimates are adjusted for age, sos, acceletinicity, body mass linker, comorbidities, Charkson comorbidity index, pre- vious SARS-CeV-2 PCB, previous positive SARS-CeV-2 seology, influenza vaccine in year prior, pneumococcal vaccine in prior 5 years, neighborhood deprivation index, prior healthcare utilization (Tables 1, Appendix 2).
79	<u>Katikireddi et al</u> (December 20, 2021)	Scotland and Brazil	≥18 year old general population	Scotland: Delta Brazil: Gamma/Delta	ChAdOx1	Scotland: May 19- October 25, 2021 Brazil: January 18- October 25, 2021	Scotland: administrative database linkage study Brazil: evaluated VE by comparing fully vaccinated persons at day 0-13 and persons 14+ days post dose 2.





									Scotland			Brazil		
									Person-years	Number of	Vaccine effectiveness*	Person-years	Number of	Vaccine effectiveness*
									reson-years	events	(95% CI)	reison-years	events	(95% CI)
								Unvaccinated	336 942	2245	0% (ref)			
								0-2 weeks after first dose	6860	39	-15·4% (-60·6 to 17·0)	1849099	21736	0% (ref)
								Partially vaccinated†	94761	420	49·3% (43·3 to 54·6)	11701310	37802	57-9% (56-9 to 58-9)
								0–1 week after second dose	47 2 5 2	78	77·7% (71·9 to 82·3)	1601585	2688	73-2% (71-9 to 74-5)
								2-3 weeks after second dose	55318	85	83·7% (79·7 to 87·0)	1492259	1095	86-4% (85-4 to 87-3)
								4-5 weeks after second dose	65698	106	86-6% (83-6 to 89-0)	1338063	1019	83-5% (82-3 to 84-7)
								6-7 weeks after second dose	71120	134	86-8% (84-2 to 88-9)	1117 983	1019	77-9% (76-1 to 79-5)
								8-9 weeks after second dose	73540	245	79-0% (75-9 to 81-7)	862 976	863	75-6% (73-4 to 77-6)
								10-11 weeks after second dose	73212	280	79.6% (76.8 to 82.1)	651213	751	69-3% (66-3 to 72-1)
								12-13 weeks after second dose	71773	337	77-4% (74-6 to 80-0)	445 924	646	60-8% (56-6 to 64-6)
								14-15 weeks after second dose	68114	356	75.9% (72.9 to 78.6)	264128	472	59-7% (54-6 to 64-2)
								16–17 weeks after second dose	63 974	402	70.5% (67.0 to 73.7)	169692	397	50-5% (43-4 to 56-6)
								18–19 weeks after second dose	58608	508	63·7% (59·6 to 67·4)	132 459	275	42-2% (32-4 to 50-6)
								20–21 weeks after second dose	45716	598	53-6% (48-4 to 58-3)			-
								Scotland reference group: unvaccinal deprivation, comorbidities, number						
								from the analysis. In Brazil, vaccine e and temporal trend. †Partially vaccin	fectiveness was a	djusted for age, sex	deprivation, macroregion of re			
								Table 2: Vaccine effectiveness est vaccination in Scotland and Braz		lOx1 nCoV-19 ag	ainst COVID-19 hospital ad	missions or death	by length of ti	ime since two-dose
									Scotland			Brazil		
									Total samples	Positive samp	les Vaccine effectiveness* (95% CI)	Total samples	Positive sampl	les Vaccine effectiveness* (95% CI)
								Unvaccinated	26130	13698	0% (ref)	9852053	4920001	0% (ref)
								0-1 week after first dose	911	374	20.9% (8-2 to 31.9)	286 322	151 328	-9-6% (-10-5 to -8-8)
								Partially vaccinated†	15714	7176	37.6% (34.6 to 40.5)	1143423	398717	37-6% (37-3 to 37-9)
								0-1 week after second dose	5027	2025	50.2% (46.7 to 53.5)	112 391	30 550	51-3% (50-6 to 52-0)
								2-3 weeks after second dose	7141	2429	67-9% (65-9 to 69-8)	95671	7963	69-8% (69-3 to 70-4)
								4-5 weeks after second dose	8947	3387	67-3% (65-3 to 69-1)	79298	15 568	68-4% (67-8 to 68-9)
								6-7 weeks after second dose	10622	4346	63-8% (61-7 to 65-7)	60301	12 401	66-8% (66-1 to 67-5)
								8-9 weeks after second dose	11258	4633	63·3% (61·3 to 65·3)	44351	9424	65-4% (64-6 to 66-2)
								10-11 weeks after second dose	14043	6319	59·3% (57·2 to 61·4)	32 832	7103	63-2% (62-2 to 64-2)
								12-13 weeks after second dose	17300	7966	55-3% (53-0 to 57-5)	22 454	5177	58-8% (57-4 to 60-1)
								14-15 weeks after second dose	17421	7670	52.9% (50.4 to 55.2)	15305	3435	59-8% (58-2 to 61-4)
								16-17 weeks after second dose	15 442	6554	48.7% (45.9 to 51.4)	10 822	2529	58-7% (56-7 to 60-5)
								18-19 weeks after second dose		6248	44.6% (41.5 to 47.6)	7458	1852	57-7% (55-4 to 60-0)
								20-21 weeks after second dose		4718	39·1% (35·4 to 42·6)			-
								*In Scotland, vaccine effectiveness v board, interval between doses, and immunosuppression, cardiac diseas appendix 2 (pp 11–15). †Partially va	emporal trend. In e, pregnancy, puer	Brazil, vaccine effer peral period, chroni	tiveness was adjusted for age, s c kidney disease, and temporal t	ex, deprivation, ma	croregion of reside	lence, diabetes, obesity,
								Table 3: Vaccine effectiveness es vaccination in Scotland and Bra				2 symptomatic in	fection by leng	th of time since two-dose
7	'8	Abu-Raddad et al	Qatar	General population	AlphaàBetaàD	mRNA-1273	January 1 and	TND study linkir	g admi	nsitrativ	e databases.			
	-	(December 16, 2021			elta		December 5, 2021	,,	8					
		Updated January												
		26,2022)												





							A Effectiveness against Any SARS-CoV-2 Infection	B Effectiveness against Any Severe, Critical, or Fatal Covid-19
							1000- 10	2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
							C Effectiveness against Symptomatic SARS-CoV-2 Infection	D Effectiveness against Asymptomatic SAR5-CoV-2 Infection
77	Young-Xu et al (December 15, 2021)	USA	Male 65+ year old veterans in VA system	NonVOC, Alpha, Delta	Comirnaty mRNA-1273	January-September 2021	Matched case control study	





7 Machado et al (December 34, 2023) Portugal Non-institutionalized 65-410 year olds Alpha, Delta Comirnaty NRN-1273 Pebruary 2(80+) or NRN-1273 Cohort study linking administrative databases. 78 Machado et al (December 34, 2023) Portugal Non-institutionalized 65-410 year olds Alpha, Delta Comirnaty NRN-1273 Pebruary 2(80+) or NRN-1273 Cohort study linking administrative databases.	_		-					1	_						
7 Machado et al (Ocember 14, 2021) Portugal Non-institutionalized 65-e110 year olds Alpha, Delta Community Contrasty ChAdOx1 February 2 (80+1) or ming gets Contrasty (100 get 78 827) Contrasty (100 get 78 827) Portugal (100 get 78 827) Non-institutionalized (100 get 78 827) Alpha, Delta Community (100 get 78 827) Contrasty (100 get 78 827) Contrasty (100 get 78 827) Contrasty (100 get 78 827) Contrasty (100 get 78 827) Portugal (100 get 78 827) Non-institutionalized (100 get 78 827) Alpha, Delta Community (100 get 78 827) Contrasty (100 get 78 827) Contrasty (100 get 78 827) Contrasty (100 get 78 827) Contrasty (100 get 78 827) Portugal (100 get 78 827) Non-institutionalized (100 get 78 98) Alpha, Delta Contrasty (100 get 78 98) Contrestasta <thcontrasty (100 get 78 98)</thcontrasty 												ness Against La	boratory-Confir	rmed SARS-CoV-2	
7 Machado et al (Ocember 14, 2021) Portugal Non-institutionalized 65-e110 year olds Alpha, Delta Community Contrasty ChAdOx1 February 2 (80+1) or ming gets Contrasty (100 get 78 827) Contrasty (100 get 78 827) Portugal (100 get 78 827) Non-institutionalized (100 get 78 827) Alpha, Delta Community (100 get 78 827) Contrasty (100 get 78 827) Contrasty (100 get 78 827) Contrasty (100 get 78 827) Contrasty (100 get 78 827) Portugal (100 get 78 827) Non-institutionalized (100 get 78 827) Alpha, Delta Community (100 get 78 827) Contrasty (100 get 78 827) Contrasty (100 get 78 827) Contrasty (100 get 78 827) Contrasty (100 get 78 827) Portugal (100 get 78 827) Non-institutionalized (100 get 78 98) Alpha, Delta Contrasty (100 get 78 98) Contrestasta <thcontrasty (100 get 78 98)</thcontrasty 										Adjusted vaccine effect	iveness by month from full	vaccination. % (95% CI)ª		
$\left \begin{array}{c c c c c } \hline s \\ s$									Month		-			v to September)	
7 Machado et al (December 14, 2021) Pertugal Non-institutionalized Alpha, Delta Comirnaty Result February 2 (80+) or March 30 (5-79) Contrastudy linking administrative databases. 78 Machado et al (December 14, 2021) Pertugal Non-institutionalized Alpha, Delta Comirnaty Result February 2 (80+) or March 30 (5-79) Contrastudy linking administrative databases. 78 Machado et al (December 14, 2021) Pertugal Non-institutionalized Alpha, Delta Comirnaty Result February 2 (80+) or March 30 (5-79) Contrastudy linking administrative databases. 78 Machado et al (December 14, 2021) Pertugal Non-institutionalized Alpha, Delta Comirnaty Result February 2 (80+) or March 30 (5-79) Contorstudy linking administrative databases. 78 Machado et al (December 14, 2021) Pertugal Non-institutionalized Alpha, Delta Comirnaty Result February 2 (80+) or March 30 (5-79) Contorstudy linking administrative databases. 78 Machado et al (December 14, 2021) Pertugal Non-institutionalized Alpha, Delta Contrastudy Result February 2 (80+) or March 30 (5-79) Contorstudy linking administrative databases. 79 March 30 (5-79) Narch 30 (5-79) Narch 30 (5-79)															
$ \begin{bmatrix} \\ \\ $															
7 Machado et al (December 14, 2021) Portugal Non-institutional/add 65-<110 year olds Alpha, Delta Comiraty mNA-1273 ChAdOx1 February 2 (80-) or March 30 (55-79) Contrative databases. 1 (December 14, 2021) Portugal Non-institutional/add 65-<110 year olds															
Machado et al 2021 Portugal Non-institutionalized 65<110 year olds Alpha, Delta Alpha, Delta Comirnaty mRNA-1273 February 2 (80+) or March 30 (5-79)- August 2021 Cohort study linking administrative databases. Machado et al 2021 Portugal Non-institutionalized 65<110 year olds															
$\left[\begin{array}{c c c c c c } \hline & & & & & & & & & & & & & & & & & & $															
76Machado et al (December 14, 2021)PortugalNon-institutionalized 65-<110 year oldsAlpha, DeltaComiraty mRNA-1273 ChAdOx1February 2 (80+) or Mark 2021Cohort study linking administrative databases.76Machado et al (December 14, 2021)PortugalNon-institutionalized 65-<110 year olds															
7 Machado et al (December 14, 2021) Portugal Non-institutionalized 65-<110 year olds															
76Machado et al (December 14, 2021)PortugalNon-institutionalized 65-<110 year oldsAlpha, DeltaComirnaty RRNA-1273 ChAdOx1February 2 (80+) or August 2021Cohort study linking administrative databases.76Machado et al (December 14, 2021)Non-institutionalized 65-<110 year olds															
76 Machado et al (December 14, 2021) Non-institutionalized 65-<110 year olds Alpha, Delta Comirnaty nRNA-1273 ChAdOx1 February 2 (80+) or March 30 (65-79)- August 2021 Cohort study linking administrative databases. 1 1 4 65-<110 year olds									0	104	INA		27.0 (10.0-30.4	-)	
76Machado et al (December 14, 2021)PortugalNon-institutionalized 65-<110 year olds									SARS-CoV-2 January to S	Infection by Delta Variar September 2021	e Preiod,	e-Delta ph Delta			
Image: December 14, 2021) Chados March 230 (b5-79) cars March 30 (b5-79) cars									-04 0 0 0		5 6 7				
2021) ChAdOx1 August 2021		76		Portugal		Alpha, Delta			Cohort	study linking adr	ninistrative data	abases.			
Convolver Adgebricity dose 1 CO21 dose 2 65-79 years 80-<110 years 65-79 years 80-<110 years 65-79 years 80-<110 years 14-41 days 79 (76-83) 72 (61-79) 95 (90-97) 83 (68-91) 95 (88-98) 87 (71-93) 70-40 vas 93 (80-60) 97 (92-98) 81 (66-90) 97 (92-98) 88 (78-91) 70-97 days 59 (53-64) 53 (43-62) 74 (60-84) 86 (78-91) 98-123 days 50 (40-59) 74 (58-83) 80 (71-86) 98-123 days 50 (40-59) 74 (58-83) 80 (71-86) 124+days 42 deg vas (42-54) 63 (37-78) 75 (64-82) 14-41 days 48 (42-54)					65-<110 year olds				timing no	-	hassita	lization		la a tha	
			2021)				ChAdOx1	August 2021							
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$															
										00 (04-71) 04 (53		01 (00-90)		00 (70-94)	
										59 (53-64) 53 (43		74 (60-84)	33 (07-90)	86 (78-91)	
98-123 days 50 (40-59) 74 (58-83) 80 (71-86) 124+days 34 (29-48) 63 (37-78) 75 (64-82) iming post AZ disease year olds - - - 14-41 days 48 (42-54) - - - 42-69 33 (23-42) - - - -											~_/	, , (00-04)		50 (70 51)	
124+days 34 (29-48) 63 (37-78) 75 (64-82) MZ disease in 65-75 year olds in 65-75 year olds in 65-75 year olds in 64-75 year olds in 64-75 year olds 14-41 days 48 (42-54) 42-69 33 (23-42) in 64-10 in 64-10											-59)	74 (58-83)		80 (71-86)	
timing post AZ disease in 65-79 in 65-79 year olds 141 days 144-1 days 48 (42-54) 24-69 33 (23-42)															
timing post in 65-79 dose 2 year olds 14-41 days 48 (42-54) 42-69 33 (23-42)												()		(
dose 2 year olds 14-41 days 48 (42-54) 42-69 33 (23-42)									timing po						
14-41 days 48 (42-54) 42-69 33 (23-42)															
									14-41 da	/s 48 (42-54)					
70+ 34(10-52)									42-69	33 (23-42)					
									70+	34 (10-52)					
75 Florea et al USA ≥18 year olds Kaiser NonVOC, mRNA-1273 December 18, 2020- Cohort study		75	Florea et al	USA	>18 year olds Kaiser	NonVOC	mRNA-1273	December 18 2020-	Cohort	tudv					
				000			1111117 12/3		conorts	, cauy					
(December 14, Permanente insured Alpha, Delta September 30, 2021						Alpha, Delta		September 30, 2021							
2021) patients			2021)		patients										
(undated April			(updated April												
	1		28, 2022)						1						







							100 95.9 97.4 94.8 94.5 % 80 88.0 84.5 177.0 75.5 60 60 60 75.5 100 100 90 20 90 90 100 100 0 0 100 100 100 100 100 0 0 100 100 100 100 100 100 0 0 100 100 100 100 100 100 100 0 0 100 100 100 100 100 100 100 0 0 10
73	Berec et al (December 12, 2021)	Czech Republic	General population	Alpha, Delta	Comirnaty mRNA-1273 ChAdOx1 Ad26.COV2.S	December 27, 2020- November 21, 2021	Cohort study of population of Czech Republic using administrative databases, evaluating duraiton of protection of primary and ve of boosted mRNA.







72	Bjork et al (December 9, 2021) (Updated March 2, 2022)	Sweden	General population	Alpha, Delta	Comirnaty mRNA-1273 ChAdOx1	March 8-November 7, 2021	Table 1. Estimated increase of breakthrough infection hazard ratios (IRts) in times of the SAIBS-CoV-2 delta variant dominance for age groups having started vaccination in the same month. $\frac{Vaccine [March (age 70.890)]}{HR} (age 50.800) [Mar (agg 53.54y)]} March (agg 53.54y)} March (agg 53.54y) [March (agg 53.54y)]} March (agg 53.54y) [March (agg 53.54y)]} March (agg 53.54y) [March (agg 50.800)] March (agg 53.54y)]} March (agg 53.54y) [March (agg 53.54y)] March (agg 53.54y)] March (agg 53.54y) [March (agg 50.800)] March (agg 53.54y)] March (agg 53.54y) [March (agg 50.800)] March (agg 53.54y)] March (agg 53.54y) [March (agg 53.54y)] March (agg 53.54y)] March (agg 53.54y) [March (agg 53.54y)] March (agg 53.54y) [Mar$
71	<u>Kshirsagar et al</u> (December 9, 2021)	USA	Fully vaccinated persons	NonVOCs, Alpha, Delta	Comirnaty mRNA-1273 Ad26.COV2.S	March 10-October 14, 2021	Cohort study of fully vaccinated persons evaluating risk of reinfection by vaccination. There was an increase in the rate of hospitalization starting ~110-125 days after full vaccination for all three vaccines depending on age group, with a steeper increase for Janssen.
70	Powell et al (February 18, 2022) (updated May 2022)	UK	General population with a focus on adolescents	Delta, Omicron	Comirnaty	Week 32 (~Aug 15) (16-17 yo) and Week 37 (12-15 yo) - January 12, 2022	TND study among adolescents against symptomatic disease





							A ()
69	<u>Bajema et al</u> (December 9, 2021)	USA	Veterans	nonVOCs, Alpha, Delta	Comirnaty mRNA-1273	February 1– September 30, 2021	TND among 1,896 U.S. veterans. Adjusted VE against hospitalization 14–119 days following 2^{nd} dose of Moderna vaccine dose was 89.6% (95% CI = 80.1%–94.5%) and after the 2nd Pfizer-BioNTech dose was 86.0% (95% CI = 77.6%–91.3%); at \geq 120 days VE was 86.1% (95% CI = 77.7%–91.3%) for Moderna and 75.1% (95% CI = 64.6%–82.4%) for Pfizer-BioNTech.
67	<u>Goldberg et al</u> (December 5, 2021)	Israel	General population	Delta	Comirnaty	August 1-September 31, 2021	Analysis of surveillance data comparing the following groups: Recovered: Previously infected individuals 90 or more days after confirmed infection who had never been vaccinated; Recovered then Vaccinated: Previously infected individuals who later were 7 or more days after receiving a single vaccine dose; Vaccinated then Recovered: Individuals who had been vaccinated with one or two doses and were later infected; Vaccinated: Individuals seven days or more after receiving the second dose, and who had not been infected before the start of the study period; Booster: Individuals who received a third (booster) dose 12 or more days previously and had not been infected before the start of the study period.





							A. Recovered Recovered 4.6 months Recovered 6.8 months Recovered 10-12 months Recovered 10-12 months Recovered 12+ months 0 10 20 30 40 50 60 70 80 90 B. Vaccinated and Booster Vaccinated 2.4 months Vaccinated 2.4 months 0 10 20 30 40 50 60 70 80 90 C. Hybrid Immunity Rec then Vacc 0.2 months 0 10 20 30 40 50 60 70 80 90 C. Hybrid Immunity Rec then Vacc 2.4 months 0 10 20 30 40 50 60 70 80 90 C. Hybrid Immunity Rec then Vacc 2.4 months 0 10 20 30 40 50 60 70 80 90 Figure 3: Estimated covariate-adjusted rates of confirmed infections per 100,000 at-risk days obtained from the Poisson regression analysis for the study period August 1, 2021, to September 30, 2021, stratified by sub-cohorts. Confidence intervals are not adjusted for multiplicity.
64	Hall et al* (February 16, 2022) [Update to (December 1, 2021 preprint]	UK	18+ year HCWs	AlphaàDelta	Comirnaty AZD2222	December 7, 2020- September 21, 2021	Cohort study of HCWs looking a VE against infection over time in those with and without prior infection. Pfizer long interval is doses separated by ≥6 weeks; short interval by <6 weeks







1							A BNT162b2 Vaccine, Long Interval between Doses
							82 90 _ T 5 80 _ T
							<u><u><u></u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u></u>
							30- 220- 10- 10-
							1 2 20-
							14–73 Days 74–133 Days 134–193 Days 194–239 Days after after after after
							dose 2 dose 2 dose 2 dose 2
							Vaccination Status
							B BNT162b2 Vaccine, Short Interval between Doses
							100-
							2 90- J
							9 50
							a b b b b b b b b c b b b b b b b b b b b b b b b b b b b b b b b b b b b b b c b c
							\$ 30- ⊥ ⊥
							8 20-
							0
							after after after after dose 2 dose 2 dose 2 dose 2
							Vaccination Status
							Vaccination status
							C ChAdOx1 nCoV-19 Vaccine
							2 100]
							2 90- T
							S 80-
							₹ 70
						1	
						1	au au bu au bu
							14-73 Days 74-133 Days 134-220 Days after after after
							arter arter arter dose 2 dose 2 dose 2.
						1	Vaccination Status
						1	
2	Israel et al	Israel	18+ years	Delta	Comirnaty	May 15-September	Test-negative design case control using administrative database of Leumit Health Services among
	(November 25,					17, 2021	2-dose vaccine recipients. Compared with the initial 90 days after the vaccine, they found an
	2021)					1	increased risk of infection with time elapsed since vaccination.
	(updated with					1	
						1	
	results from					1	
	publication, see						
	ref 2 below)				1		







							Table 4 Adjusted odds ratios for risk of SARS-CoV-2 in matched cohort Adjusted odds ratio (95% CI) P value Time since second vaccine (days): -<
							Socioeconomic status (continuous 1-20) 0.97 (0.96 to 0.98) <0.001 Based on a conditional regression model fitted in a cohort matched for week of testing, age category (c18-39, 40-59, >60 years), and demographic group.
8	Irizarry et al (November 19, 2021)	USA (Puerto Rico)	12+ years	Predelta and delta	Comirnaty mRNA-1273 Ad26.COV2.S	December 15, 2020- October 15, 2021	Analysis of surveillance data linked to immunization registry data. VE against B) Infection c) Hospitalizations D) death by time since 2 weeks post complete series completion. Shading represents 99% CI. y_{0}^{0} y_{0}^{0} y_{0
61	Andrews et al (November 15, 2021)	UK	50+	Delta	Comirnaty AZD2222	September 13- November 1, 2021	TND booster dose study that also calculated the VE of a 2 nd dose >140 days after receipt of the 2 nd dose. VE against symptomatic diseaes for two doses of ChAdOx1-S and BNT162b2 ≥20 weeks after being given were 44.1% (41.9 to 46.1) and 62.5% (61.0 to 63.9), respectively.
59	Tenforde et al (November 4, 2021)	USA	Hospitalized patients	Mix, alpha, and delta	Comirnaty mRNA-1273	March 11-August 15, 2021	Case-control study among hospitalized patients. When the mRNA-1273 and BNT162b2 vaccines were compared, estimated vaccine effectiveness was similar within 120 days of vaccination. In contrast, beyond 120 days, the results corresponded to an estimated effectiveness of 85% for the mRNA-1273 and 64% for the BNT162b2 vaccine to prevent COVID-19 hospitalizations.
58	Poukka et al (November 4, 2021)	Finland	16-69 year old HCWs	Mix and delta	Comirnaty mRNA-1273 AZD2222 heterologous	December 27,2020- August 26 (infection) October 26 (hospitalization), 2021	HCW cohort study based on registries. No difference seen between delta and pre-delta periods. VE against infection





56 Skowronski et al (October 26, 2021) (updated April 19, 2022) Canada Gr	ieneral population Alpha, Gamma, Delta	AZD1222 Comirnaty mRNA-1273 And heterologous schedules of the above	May 30, 2021 - November 27, 2021	TND study in BC and Quebec. In both provinces, all homologous or heterologous mRNA and/or ChAdOX1 two-dose 12 schedules to series to seek of 390%. VE against infection visk of at least 7 13 months. With sight decline from a peak of 390%. VE against infection visk of at least 7 13 months. With sight decline from a peak of 390%. VE against infection visk of at least 7 13 months. With sight decline from a peak of 390%. VE against infection visk as 280% for at least 7 13 months. With sight decline from a peak of 390%. VE against infection visk as 280% for at least 7 13 months. With sight decline from a peak of 390%. VE against infection visk as 280% for at least 7 13 months. With sight decline from a peak of 390%. VE against infection visk as 280% for at least 7 13 months. With sight decline from a peak of 390%. VE against infection visk as 280% for at least 7 13 months. With sight decline from a peak of 390%. VE against infection visk as 280% for at least 7 13 months following homologous mRNA vaccination, lower by "10% when both doese were 15 ChAdOX1 but comparably-high following heterologous to the provinces and the provinces are set of 190%. The peak of 190% is the peak of 190%. The peak of 190% is the peak
---	---	---	-------------------------------------	---








55	Lin et al (October 26, 2021) [updated with final publication on January 12, 2022}	USA	General population	multiple	Comirnaty mRNA-1273 Ad26.COV2.S	December 13, 2020- Sept 8, 2021	Administrative database cohort study in North Carolina. For Pfizer two-dose,VE peaks at 94.5% (95% CI, 94.1 to 94.9) at 2 months (post the first dose). VE starts to decline after 2 months and drops to 66.6% (95% CI, 65.2 to 67.8) at 7 months. For Moderna two-dose,VE peaks at 95.9% (95% CI, 95.5 to 96.2) at 2 months. Effectiveness started to decline after 2 months and was maintained at 80.3% (95% CI, 79.3 to 81.2) at 7 months. For the Janssen one-dose regimen, vaccine effectiveness ramps to a peak level of 74.8% (95% CI, 72.5 to 76.9) at 1 month. Effectiveness started to decline after 1 month and decreased to 59.4% (95% CI, 57.2 to 61.5) at 5 months.











54	Nordstrom et al (October 25, 2021) [Updated February 4, 2022]	Sweden	General population	Alpha, Delta,	AZD1222 Comirnaty mRNA-1273 And AZD1222à mRNA-1273	January 12-October 4, 2021	National cohort study based on database linkage. Vaccine effectiveness of BNT162b2 against infection waned progressively from 92% (95% Cl, 92-93, P<0·001) at day 15-30 to 47% (95% Cl, 39-55, P<0·001) at day 121-180, and from day 211 and onwards no effectiveness could be detected (23%; 95% Cl, -2-41, P=0·07). The effectiveness waned slightly slower for mRNA-1273, being estimated to 59% (95% Cl, 18-79) from day 181 and onwards. In contrast, effectiveness of ChAdOx1 nCoV-19 was generally lower and waned faster, with no effectiveness detected from day 121 and onwards (-19%, 95% Cl, -97-28), whereas effectiveness from heterologous ChAdOx1 nCoV-19 / mRNA was maintained from 121 days and onwards (66%; 95% Cl, 41-80). Overall, vaccine effectiveness was lower and waned faster among men and older individuals. For the outcome severe Covid-19, effectiveness waned from 89% (95% Cl, 82-93, P<0·001) at day 15-30 to 42% (95% Cl, -35-75, P=0·21) from day 181 and onwards, with sensitivity analyses showing notable waning among men, older frail individuals, and individuals with comorbidities.
52	Hulme et al (October 18, 2021)	UK	HCW	Alpha, delta	Comirnaty AZD1222	January 4-June 13	Comparative VE Cohort study of HCWs based on linking databases who were vacinated with ADD1222 or Comirnaty between January 4-February 28, 2021 who were followed for 20 weeks. Fur 42 Comparative effectiveness. For each outcome based on the fully adjusted model, the marginal comfastive indexes on comfound adjustment, and the base transie or comfound adjustment adjust explosion.
51	Robles-Fontan et al (October 18, 2021)	USA (Puerto Rico)	General population	Multiple, with delta time frame analysis	Comirnaty mRNA-1273 Ad26.COV2.S	December 15,2020- October 15, 2021	Cohort study of Puerto Rican population.





	(updated March						Outcome	Vaccine	Effectiveness	on first day as fully va	ccinated (CI)	Effectiveness after 144 days (CI)	
	2, 2022)	1	1				Infection	mRNA-1273 BNT162b2	90% (88-91%) 87% (85-88%)			72% (69-75%)	
		1	1				Infection	Ad26.COV2.S	87% (85-88%) 64% (58-69%)			54% (51—57%) 36% (31—42%)	
		1	1				Hospitalization	mRNA-1273	95% (89-97%)			30% (31-42%) 91% (84-95%)	
							Hospitalization	BNT162b2	92% (86-95%)			81% (74-86%)	
							Hospitalization	Ad26.COV2.S	82% (61-91%)			57% (54-77%)	
							Death	mRNA-1273	99% (89-100%			93% (81-97%)	
							Death	BNT162b2	97% (87-99%)			86% (76-92%)	
							Death	Ad26.COV2.S	78% (14-94%)			73% (49-86%)	
							beau	74201001215	10/0 (11) 1/0/		,	5.0000	
50	De Gier et al (October 14,	Netherlands	General population	Delta	Comirnaty mRNA-1273	August 9-September 24, 2021	Study of ur		and vaccina	ated index o	ases and the		aluate transmission. ssion differed by time
	2021)				Ad26.COV2.S AZD1222		Table S2. Seco (< or >= 60 da week of notifi	nation of the ondary attack rate o lys, only in analysis	f SARS-CoV-2 and of fully vaccinate	d VET adjusted for d contacts), age g		ination of the contact se and contact and	
							Analysis	Unvaccinated index - infected contacts / all contacts (SAR)	Index fully vaccinated < 60 days ago - infected contacts / all contacts (SAR)	Index fully vaccinated < 60 days ago - adjusted VET (%) (95% CI)	Index fully vaccinated >= 60 days ago - infected contacts / all contacts (SAR)	CI)	
							Unvaccinated household contacts	547/2517 (22%)	24/209 (11%)	67 (47;79)	14/94 (15%)	55 (19;76)	
							Fully vaccinated household contacts	164/1505 (11%)	99/1278 (8%)	57 (40;69)	157/792 (20%)	28 (-4;50)	
49	Janssen Briefing document for US FDA (October 14, 2021)	multiple	General population	Multiple	Ad26.COV2.S	September 21, 2020- July 9, 2021	v F Vacci	accine Efficacy O	1 Day After Vac buble-Blind Phase for Seronegative for Seronegative to SevereCritical COVID-	cination, PP Set	(Seronegative; Stud ocal Efficacy Set)	ere/Critical COVID-19 y VAC31518COV3001)	
											Last event: d Base	day 229; Hazard smoothed over 21 days. ed on the methods in Gilbert et al. (2002).	





							Table 3:Vaccine Efficacy of Molecularly Confirmed Moderate to Severe/Critical COVID-19 with Onstei at Least 1 Day After Vaccination; Per Protocol Set Final Analysis of Double-Blind Phase Study (VAC31518COV3001) https://www.severeicularly-confirmed-Moderate to Severe/Critical CovID-19Day 10 to Day 14Ad26 5:01 vpPlaceboModerate to severeicularly#Cases (N) PYModerate to severeicularly#Cases (N) PYDay 15 to Day 28\$1 (1900) 1483.44148 (19398) 1480.09Day 29 to Day 56\$1 (1900) 123 277.4230 (1824) 2837.44Day 57 to end DB Phase\$14 (17586) 6460.98573 (1700) 6158.91Day 57 to end DB Phase\$15 (11379) 4900.35265 (10572) 4529.34Day 75 to Day 112\$15 (11379) 4900.35265 (10572) 4529.34Day 113 to end DB Phase\$157 (11379) 4900.35265 (10572) 4529.34Moderate to SevereiCritical COVID-19 with Onset at Least 1 Day After Vaccination, PP Set (Seronegative; Study VAC31518COV3001) Final Analysis Onbulbe-Blind PhaseStatistical filter over Time of Molecularly Confirmed SevereiCritical COVID-19 with Onset at Least 1 Day After Vaccination, PP Set (Seronegative; Study VAC31518COV3001) Final Analysis of Double-Blind PhaseStatistical filter over Time of Seronegative Patients (Per Protocal Efficacy Set)Moderate of SevereiCritical CovID-19Moderate of SevereiCritical CovID-19Moderate of SevereiCritical CovID-19Moderate of SevereiCritical CovID-19Moderate of SevereiCr
48	Rosenberg et al (October 9, 2021) Updated with final publication on December 1, 2021	USA	General adult population of New York	Delta for part of study period	Comirnaty mRNA-1273 Ad26.COV2.S	May 1-September 3, 2021	Cohort study based on administrative datbases. Estimated VE for cases declined contemporaneously across age, products, and time-cohorts. VE for hospitalization for adults 18-64 years was >86% across cohorts, without time trend.
47	<u>Liu et al</u>	USA	General population of NYC	Alpha, Delta, others	Comirnaty mRNA-1273	January 18- September 21, 2021	Hospital database cohort study. They found that there was an increased incidence rate with the increased time from vaccination, especially 120 days after vaccination.





	(October 7, 2021)						see 0.16- 000 0.10- 9000 0.00- 0 5 50 10 10 10 Time to fully vacuin	o zòo zào ated (days)	moderna pfizer					
								Pfizer/BN	T162b2		Moderna/	mRNA-1273		
							Time to fully vaccination	Total person-days at risk ¹	Incidence	Incident rate / 1000 person-days	Total person-days at risk	Incidence	Incident rate / 1000 person-days	
							210-240 days	3074	6	1.952	443	1	2.257	
							180-210 days	16811	24	1.428	5543	5	0.902	
							150-180 days	34847	16	0.459	16525	6	0.363	
							120-150 days 90-120 days	66486 105697	27 15	0.406	32243 52162	7 5	0.217	
							60-90 days	150864	15	0.142	74806	5	0.096	
							30-60 days	203392	26	0.128	100706	5	0.050	
							0-30 days	259596	26	0.100	126977	8	0.063	
46	<u>Italian Instituo</u> <u>Superiore di</u> <u>Sanita</u> (September 30, 2021)	Italy	≥16 year old general population who received at least 1 dose of mRNA vaccine	Alpha, Delta	Comirnaty mRNA-1273	December 27, 2020- August 29, 2021	observe a redu COVID-19 diagr with subsequer about 6 month immunocompo wide for the lat	ction of the nosis, afte nt hospita s. Person rmised di	e protect r about se lization (\ s >80+, nt d see a de 2,475,475,844) v e e d e e e d e e e d e e e d e e e e e	Live effect even mon /E 96%), a ursing hor ecline in V	coses: 2,765; p	nation, aga the 2nd d to ICU (V nts, perso	ainst symp dose (VE 85 /E 96%), or ons with cc though cc //18,702,727)	c dose 1. They did not tomatic or asymptomatic 9%), nor against diagnosis death (VE 99%) after omorbidities or onfidence intervals are
45	<u>Martinez Bas et</u> <u>al</u>	Spain	≥18 year old general population	Alpha, Delta	Comirnaty mRNA-1273 AZD1222	April 1-August 31, 2021	Cohort study of	f contacts	of cases.					





	(September 30, 2021)				Ad26.COV2.S		Adjust VE (95% Cl) <90 days since last dose ≥90 days since last dose unvaccinated REF REF 1 dose of Janssen 52 (44-59) 28 (-8-53) 1 dose of Spikevax 65 (56-73) NA 2 doses of Spikevax 85(80-88) 67 (50-78) 1 dose of Comirnaty 57 (51-61) NA 2 doses of Comirnaty 70 (67-73) 63 (58-68) 1 dose of Vaxzervia 40 (31-47) 52 (37-64) 2 doses of Vaxzervia 54 (47-60) NA 1 dose of Vaxzervia+1 dose of Comirnaty 85 (69-93) NA
44	Bruxvoort et al (October 1, 2021)	USA	General population	Delta, Alpha+others	mRNA-1273	March 1-July 27, 2021	TND study among persons insured by Kaiser Permante Southern California.
43	<u>Payne et al</u> (July 21, 2021)	UK	HCWs	Alpha	Comirnaty	December 7, 2020- March 12, 2021	Cohort study of HCWs





							Hazard rate ratio estimate (full model, 1st Dose) Hazard rate ratio estimate (full model, 1st Dose) Hazard rate ratio estimate (full model, 2nd Dose)
41	Eyre et al* (January 5, 2022) [Update to September 29, 2021 preprint]	UK	contacts of symptomatic and asymptomatic SARS- CoV-2-infected index cases	Alpha/Delta	Comirnaty AZD1222	January 1-July 31, 2021	Transmission study. Independently of contact vaccination status, for each doubling of weeks since 14 days after second vaccinationin index cases, the odds of a contact testing PCR-positive increased 1.13-fold (95%Cl 1.09-1.17) for ChAdOx1 and 1.20-fold (1.10-1.31) for BNT162b2 with no evidence of a difference between vaccines (p=0.19). Higher probabilities of PCR-positive results in contacts 14 days after second vaccination for Delta vs. Alpha meant that by 12 weeks post second ChAdOx1 dose there was no evidence that onward Delta transmission rates differed between those not vaccinated and those having received two ChAdOx1dosesand the impact of BNT162b2had also attenuatedsubstantially
40	<u>Nunes et al</u> (September 23, 2021)	Portugal	Cohort of 80-109 year olds	Multiple	Comirnaty mRNA-1273	February 2-August 13, 2021	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$
37	Pilishvili et al (September 22, 2021)	USA	HCW	Multiple	Comirnaty mRNA-1273	December 28-May 19, 2021	TND case control among HCWs evaluated VE every 2 weeks for 14 weeks.





							$\begin{array}{c} 100 \\ 90 \\ 90 \\ 10 \\ 90 \\ 90 \\ 10 \\ 1-2 \\ 3-4 \\ 1-2 \\ 3-4 \\ 5-6 \\ 7-8 \\ 9-10 \\ 11-12 \\ 13-14 \\ 11-12 \\ 13-14 \\ 13-14 \\ 13-14 \\ 14 \\ 14 \\ 14 \\ 14 \\ 14 \\ 14 \\ 14 \\$
36	El Sahly et al (September 22,	USA	RCT participants	Multiple	mRNA-1273	July 27, 2020-March 26, 2021	No. of Cases 40 10 16 24 23 35 24 No. of Controls 541 213 156 137 99 139 88 Findings from the double blinded placebo controlled RCT. VE against disease was similar at 2 weeks-<2 months (91.8%), 2 months-<4 months (94%), and ≥4 months (92.4%) post dose 2
	(September 22, 2021)					26, 2021	weeks-<2 months (91.8%), 2 months-<4 months (94%), and 24 months (92.4%) post dose 2
35	Baden et al (September 22, 2021)	USA	≥18-year-old RCT participants	Delta	mRNA-1273	July 1-August 27, 2021	RCT participants were followed after unblinding. Initial vaccine recipients (mRNA-1273e) were vaccinated between 7/27/20-12/16/20 while those vaccinated after unblinding (mRNA-1273p) were vaccianted between 12/29/20-4/30/21. Median follow-up times from the first dose were 13 months in the mRNA-1273e (including double-blind and open-label phases) and 7.9 months in the mRNA-1273p (only open-label phase) groups. While there was a significant difference in disease incidence rates between the groups, there was no difference in severe disease incidence rates though numbers are small.
							mRNA-1273e mRNA-1273p* mRNA-1273p vs
							N=14746 N=11431 mRNA.1273e Covid-19 Cases Person- Rate/1000 Cases Person- Rate/1000 Reduction of observed
							Cases† n yr Person-yr incidence rate % (95% Cl) All cases 162 2102 77.1 88 1796 49.0 36.4 (17.1-51.5)
							≥18-<65 yr 136 1558 87.3 68 1289 52.8 39.6 (18.6-55.5)
							265 yr 26 544 47.8 20 507 39.5 17.4 (-53.9-56.3) 2000 400 0.0 400 0.0 400 0.0
							Severe 13 2102 6.2 6 1796 3.3 46.0 (-52.4-83.2) ≥18-<65 7 1558 4.5 4 1289 3.1 30.9 (-171.7-85.2)
							yr 6 544 11.0 2 507 3.9 64.2 (-10.2-96.5)
34	Hagan et al (September 21, 2021)	USA	Incarcerated persons	Delta	Comirnaty mRNA-1273 Ad26.COV2.S	July 11-August 14, 2021	Outbreak investigation in a prison found that the attack rate among fully vaccinated persons was significantly higher in those vaccinated 4-6 months ago (89%) compared to those vaccinated 2 weeks-2 months ago (61%). This was combined for 3 vaccines used in the population.
33	Thomas et al (September 15, 2021)	Multiple	≥12-year-old RCT participants	Multiple	Comirnaty	July 27, 2020-March 13, 2021	Findings from the double blinded placebo controlled RCT. VE against disease was 96.2% (93.3-98.1) at 7 days-<2 months, 90.1% (86.6-92.9) at 2 months-<4 months, and 83.7% (74.7-89.9) at ≥4 months post dose 2.





٦

							Efficacy End Point BNT152b2 (N=23,040) Placebo (N=23,047) Vacine Efficacy No. of case Surrelliance imm No. of case Surrel
32	Pfizer (September 17, 2021)	Multiple	≥16-year-old RCT participants	Delta	Comirnaty	July 1-August 31, 2021	RCT participants were evaluated for duration of protection against symptomatic disease, with the original placebo recipients receiving the vaccine after unblinding. The mean time from Dose 2 of Comirnaty to 01 July 2021 was approximately 5 months for the crossover group and 10 months for the original group. There was a 26.3% (7.4%- 41.4%) relative vaccine efficacy for the group vaccinated later (crossover group) compared to the group vaccinated earlier (original group), with a difference in incidence rates of -18.6 per 1000 person-years of follow-up.
31	<u>de Gier et al</u> (September 17, 2021)	Netherlands	Hospitalized patients	Delta (just for duration of protection)	Comirnaty mRNA-1273 Ad26.COV2.S AZD1222	July 4-August 29, 2021 (just for duration of protection)	Incidence rate ratios were calculated based on national coverage and vaccination status of hospitalized cases. All 4 vaccines were combined in calculating the VE by time since vacciantion, and VE was only calculated during the delta dominant period when 99% of sequenced isolates were delta. No drop in VE against hospitalization nor in VE against ICU admission was seen between those vaccinated up to 20 weeks since full vacciantion among 15-49, 50-69, ≥70 year olds.
30	<u>Self et al</u> (September 17, 2021)	USA	≥18 years who were hospitalized at 21 U.S. hospitals across 18 states	Alpha, Delta, Non-VOC	Comirnaty mRNA-1273 Ad26.COV2.S	March 11–August 15, 2021	This case-control study found that the for mRNA-1273 vaccine, there was no difference in VE against hospitalization among those were 14-120 days post full vaccination and those who were >120 days post full vaccination. For Comirnaty, VE against hopsitalization was 91% (88-93) for those 14-120 days post full vaccination while it was 77% (67-84) for those >120 days post full vaccination. Ad26.COV2.S did not have enough data to stratify by more than 28 days post full vaccination.
29	Polinski et al (September 12, 2021) (updated March 17, 2022)	USA	≥18 years of age	Alpha/Delta	Ad26.COV2.S	March 1, 2021- August 31, 2021	Retrospective cohort study used insurance claims data linked to health data sources to evaluate VE of Ad26.COV2.S against COVID-19 diagnosis and hospitalization among vaccinated individuals and matched unvaccinated individuals (matched on age, sex, comorbid-risk, calendar date, location, and other risk factors for COVID-19 severity). VE was stable over time up to 152 days after vaccination.
28	McKeigue et al (September 15, 2021) (updated February 25, 2022)	Scotland	Population of Scotland	Alpha/Delta	Comirnaty mRNA-1273 AZD1222	December 1, 2020- September 8, 2021	Matched case-control study (REACT-SCOT) assessed rate ratios over time comparing rate of severe COVID-19 and the rate of hospitalization or death among thoswe full vaccinated with Comirnaty, mRNA-1273, and AZD1222 to unvaccinated persons.







							<figure>Fr - 2 does RHs In te 2-dyrine widow certred on 20 weeks from the most recert vacione does are specific to the same maximum thickness for each effect BR-rate ratio.</figure>
27	Bajema et al (September 10, 2021)	USA	Veterans ≥ 18 years	Alpha/Delta	BNT162b2 & mRNA-1273	February 1, 2021- August 6, 2021	Test-negative case-control study of adults hospitalized at 5 Veterans Affairs with COVID-like illness. No difference was found in VE against hospitalization <90 days vs. ≥ 90 days post second dose of BNT162b2 or mRNA-1273: 86.1% (76.5-91.8%) vs. 87.2 (78.2-92.5%).
26	Andrews et al With updated data through August 20 th here (September 14, 2021) Updated with final publication	UK	Symptomatic cases and test-negative controls 16 years and older	Alpha/Delta	Comirnaty mRNA-1273 AZD1222	December 8, 2020- September 3, 2021	This test-negative case-control study assessed VE of 2 doses of Comirnaty, mRNA-1273, and AZD1222 against symptomatic disease, hospitalization, and death over time separately for Alpha and Delta variants. VE against symptomatic disease peaked in early weeks post 2nd dose and then declined for Comirnaty and mRNA-1273 for both Alpha and Delta. Waning was greater for Delta than Alpha. Only limited waning against hospitalization and death was observed.







	on January 12,						Variant ⊘Alpha ■ Delta
1	2022						A Symptomatic Disease
							ChAdOx1.S BNT162b2
							B Hospitalization Ch4Ox1.5 BNT162b2 BNT162b2 BNT162b2 BNT162b2 BNT162b2 BNT162b2 Ch4Ox1.5 BNT162b2 Ch4Ox1.5 Ch4Ox1.5 BNT162b2 Ch4Ox1.5 Ch4Ox1.
							Weeks since Dose 2 C Death BNT162b2 00- 0 00-
							Figure 1. Vaccine Effectiveness against Symptomatic Covid-19 and Related Hospitalization and Death in England. Waning was also greater for those 65+ years compared to 40-64 year-olds and in those in a clinical risk group and clinically extremely vulnerable group. Data for mRNA-1273 was only available thorugh 10-14 weeks post 2nd dose for symptomatic disease and shows high VE (85.6%) at 10-14 weeks.
25	<u>Dagan et al</u> (September 9, 2021)	Israel	Pregnant women	Alpha/Delta	Comirnaty	December 20, 2020- June 3, 2021	Cohort study of pregnant women that showed no drop in VE through 56 days post dose 2
24	<u>Thompson et al</u> (September 9, 2021)	USA	≥50 years of age	Multiple including alpha/delta	Comirnaty mRNA-1273 Ad26.COV2.S	January 1-June 22, 2021	Test negative case control study that found that VE against hospitalization remained >80% through at least 112 days post the dose 2 for Comirnaty and mRNA-1273. For Ad26.COV2.S, VE stayed high at time point ≥56 days after vaccination. VE against ER/urgent care visit is >80% through at least 112 days post dose 2 for Comirnaty and mRNA-1273. For Ad26.COV2.S, VE stayed high at time point ≥56 days after vaccination. VE against hospitalization (for all 3 vaccines combined)





							Fully vaccinated — 2 doses $14-27$ Days after dose 2 2,754 48 (1.7) H 88 (84 to 92) $28-41$ Days after dose 2 2,783 41 (1.5) H 92 (88 to 94) $42-55$ Days after dose 2 2,033 41 (1.6) H 90 (87 to 93) $56-69$ Days after dose 2 2,048 24 (1.2) H 95 (82 to 90) $7-83$ Days after dose 2 2,048 24 (1.2) H 95 (89 to 95) $84-97$ Days after dose 2 97 (1.8) H 48 (79 to 91) $98-111$ Days after dose 2 971 23 (2.4) H 48 (79 to 93) Verticenase sensions atmenative denarisationation VE against emergency froom visits/urgent care visits (for all 3 vaccines combine Fully vaccinated — 2 doses 11/70 20 (1.7) H 95 (92 to 97) $42-55$ Days after dose 2 1,067 18 (1.7) H 95 (92 to 97) $42-55$ Days after dose 2 1,067 18 (1.7) H 95 (92 to 97) $42-55$ Days after dose 2 1,067 18 (1.7) H 95 (92 to 97) $42-55$ Days after dose 2 1,067 18 (1.7) H 95 (92 to 97) <t< th=""><th></th></t<>	
23	Puranik et al (September 7, 2021)	USA	Persons ≥14 days post dose 2 ("full vaccination") who received first dose after January 1	Multiple including alpha/delta	Comirnaty	January 1-August 8, 2021	Test negative case control study to assess duration of protection against sympt Adjusted OR start showing waning at day 60 after full vaccination. Covariate Level/Category Symptomatic Infection [N = 974 positive events] Time Relative to Full vaccination Day 0 1 (Reference) Day 30 2.19 (0.89, 5.36) Day 60 3.65 (1.78, 7.46) Day 90 5.58 (2.72, 11.46) Day 120 7.25 (3.47, 15.18) Day 150 10.33 (5.03, 21.24)	comatic disease.
22	Kertes et al (September 7, 2021)	Israel	Fully vaccinated population	Delta	Comirnaty	June 9-July 18, 2021	Study of Maccabi HMO clients who were 7 days post dose 2 by June 9 and had infection. Found that those vaccinated in January-February had odds of infection 1.79) compared to those vaccinated in March-May of testing positive for SARS	on of 1.61 (1.45-
19	<u>Keehner et al</u> (September 1, 2021)	USA	~19,000 employees of University of California San Diego Health	Delta	BNT162b2 mRNA-1273	July -August 26, 2021	Cohort study of HCWs showed that among symptomatic cases occurring in July January or February had an attack rate of 6.7 per 1000 persons (95% CI, 5.9 to attack rate was 3.7 per 1000 persons (95% CI, 2.5 to 5.7) among those who con during the period from March through May. Among unvaccinated persons, the 16.4 per 1000 persons (95% CI, 11.8 to 22.9).	7.8), whereas the npleted vaccination July attack rate was
18	Nunes et al (August 29, 2021)	Portugal	1.5 million ≥65 year olds (duration of protection on only those 80+)	Alphaàdelta	BNT162b2 mRNA-1273	?February-August 13, 2021	Cohort study using electronic databases. For those 80+, VE against hospitalizat at day 14-41 and 89% (71-96) at day 98+. For COVID related mortality, it was 86 14-41 and 74 (60-83) at day 98+. Noted limitations are that data delays could r such as hospitalization/mortality have not been recorded for more recent case 6% of the 80+ cohort remained unvaccinated during the study period, making t individuals probably quite different from the vaccinated.	6% (68-93) at day mean that outcomes s. Additionally, only
17	<u>Cerqueria-Silva</u> <u>et al</u> (August 27, 2021)	Brazil	75.9 million vaccinated in Brazil	Gamma	CoronaVac AZD1222	January 18-July 24, 2021	This was a retrospective cohort study that calculated VE, as well as evaluated thospitalization incidence per 100,000 vaccinees. For CoronaVac, there was low incidence up to 84 days in vaccinees up to 79 years old. 80-89 and ≥90 age gro incidence 28 days post dose 2 but then increased but were still lower than 1 do	v hospitalization oups lowest





							A CoronaVac 4 Hundred Wart 4
16	Chemaitelly et al* (October 6, 2021) [Update to Aug 27 preprint]	Qatar		AlphaàBetaàD elta	BNT162b2	January 1-August 15, 2021	Test-negative case-control study evaluating VE by time since vaccination stratified by age, VOC, and outcome. They see a drop in VE against infection over time since vaccination with no difference by those older/younger than 60. VE against severe disease is preserved (until sample size is insufficient). A Effectiveness against Ary SAES_COV2 Infection
13	Tartof et al* (October 16, 2021)	USA	3.4 million Kaiser Permanante Southern California members ≥12 years	Delta for latter months of study	BNT162b2	December 14, 2020- August 8, 2021	Retrospective cohort study. VE against infection for the fully vaccinated decreased with increasing time since vaccination, declining from 88% (86–89) during the first month after full vaccination to 47% (43–51) after ≥5 months. Individuals ≥65 years of age had lower overall effectiveness against infections but declined at a similar rate (VE at <1 month after being fully vaccinated: 80% [73–85]; VE at ≥5 months: 43% [30–54]). Among fully vaccinated persons of all ages, protection against





	[Update to Aug 23 preprint]						COVID-19-related hospitalization did not wane over time, with overall adjusted VE estimates of 87% (82–91) at <1 month after full vaccination. At <1 month, VE against Delta: 93% (85–92) at VE against other variants: 97% (95– 99). At ≥4 months, VE against Delta infections: 53% (39–65) and VE against other variants: 67% (95– 90). At ≥4 months, VE against Delta infections: 53% (39–65) and VE against other variants: 67% (95– 90). At ≥4 months, VE against Delta infections: 53% (39–65) and VE against other variants: 67% (95– 90). At ≥4 months, VE against Delta infections: 53% (39–65) and VE against other variants: 67% (95– 90). At ≥4 months, VE against Delta infections: 53% (39–65) and VE against other variants: 67% (95– 90). At ≥4 months, VE against Delta infections: 53% (39–65) and VE against other variants: 67% (95– 90). At ≥4 months, VE against Delta infections: 53% (39–65) and VE against other variants: 67% (95– 90). At ≥4 months, VE against Delta infections: 53% (39–65) and VE against other variants: 67% (95– 90). At ≥4 months, VE against Delta infections: 53% (39–65) and VE against Delta infection: Months After Full Vacchation: 53% (95–97). At ≥50% (95–97) and 54% (95–97). At ≥50% (95–97) and 54% (95–97) and 5
12	Goldberg et al (August 24, 2021)	Israel	4.8 million fully vaccinated persons; >16 and ≥40 (depending on analysis) +unvaccinated in israel	Delta	BNT162b2	July 11-July 31 2021	The study compared the rate of breakthrough infection in July, when Delta was the dominant strain, between individuals who received 2 doses of the vaccine earlier this year to individuals who received two doses of the vaccine more recently, while adjusting for confounders. Rates of infection decline the more recently one was vaccinated; with severe disease, this is seen in those ≥60 years. A second analysis was done among the general population cohort of vaccinated and





							unvaccinated to calculate VE by age group and month of vaccination.
							Age JanB FebA FebB MarA MarB Apr May
							16-39 50% [45, 55] 47% [42, 52] 58% [55, 62] 62% [59, 64] 68% [65, 70] 74% [71, 77] 73% [67, 78]
							40-59 58% [54, 62] 61% [58, 65] 63% [59, 66] 67% [63, 70] 74% [70, 77] 78% [73, 82] 80% [71, 86]
							60+ 57% [52, 62] 63% [57, 67] 65% [57, 71] 73% [66, 78] 72% [64, 77] 73% [63, 81] 75% [58, 85]
							OUTCOME = Severe COVID-19
							Age Jan Feb Mar 40-59 94% [87, 97] 98% [95, 99] 98% [94, 99]
							60+ 86% [82, 90] 88% [84, 91] 91% [85, 95]
10	Pouwels et al* (October 14, 2021) [Update to Aug 18 preprint]	UK	General adult population	Alpha, Delta	BNT162b2 AZD1222	December 1, 2020- August 1, 2020	COVID-19 infection survey is a household longitudinal survey with testing. During the delta dominant period, in those 18 to 64 years, VE of BNT162b2 against new PCR-positives reduced by 22% (95% CI 6% to 41%) for every 30 days from second vaccination. Reductions were numerically smaller for ChAdOx1 (change -7% per 30 days, 95% CI -18% to +2%) but there was no formal evidence of heterogeneity (p=0.14).
9	Tenforde et al (August 18, 2021)	USA	Hospitalized patients	Alpha > Delta	BNT162b2 mRNA-1273	March 11-July 14, 2021	Test-negative design case control study of hospitalized patients. VE against COVID-19– associated hospitalization was 86% (95% CI = 82%–90%) 2–12 weeks and 84% (95% CI = 77%–90%) 13–24 weeks from receipt of the 2 nd dose, with no significant change between these periods (p = 0.854). There was no difference in VE by timing since vaccine among those \geq /< 65 years, immunocompromised versus not and among those with \geq /< 3 chronic conditions.





							FIGURE 2. Sustained vaccine effectiveness* against COVID-19 among hospitalized adults, by patient status ^{1,§} and interval since vaccination — 21 medical centers in 18 states, ¹ March-July 2021
8	Yassi et al (July 16, 2021)	Canada	HCWs in Vancouver	Alpha/Gamma	BNT162b2 mRNA-1273	December 15-May 13, 2021	Retrospective cohort study of HCWs linking administrative databases. At 16 weeks (day 112) post dose 1 and 2 they don't see a decline in VE. Note that day 0-13 post dose 1 is included in the unvaccinated comparison group.
7	<u>Chemaitelly et al</u> (August 9, 2021)	Qatar	Immunosuppressed kidney transplant patients	Alpha/Beta	BNT162b2 mRNA-1273	February 1-July 21, 2021	Retrospective cohort study finding VE against infection was 73.9% (95% CI: 33.0-89.9%) at day 56+ post dose 2; VE against severe/critical/fatal disease was 83.8% (95% CI: 31.3-96.2) at day 56+ post dose 2.
6	Carazo et al (July 22, 2021)	Canada	HCWs in Quebec	Alpha	BNT162b2 mRNA-1273	January 17-June 5, 2021	This is a test-negative case control linking surveillance and vaccination data from administrative databases for HCWs. Across 16 weeks, no decline in single-dose VE against infection was observed with appropriate stratification based upon prioritized vaccination determined by higher versus lower likelihood of direct patient contact. Figure 2. Vaccine effectiveness against COVID-19 by interval since vaccination







							Figure 3. Vaccine effectiveness against COVID-19 in healthcare workers vaccinated before January 31 st 2021 (highest contacts with patients) and those vaccinated after February 20 th 2021 (fewer contacts with patients) by interval since vaccination
5	Amirthalingam et al (July 28, 2021)	UK	50+ year old population	Alpha/Delta	BNT162b2 AZD1222	January 4-June 18, 2021	This is a test-negative case control study linking surveillance and vaccination data from administrative databases. In summary, VE against disease potentially declines post dose 1 at day 70+ for AZD1222 and at day 56+ for BNT162b2 but there are wide/overlapping confidence intervals making conclusions challenging. Higher two-dose VE was observed with > 6-week intervals between BNT162b2 doses compared to the authorized 3-week schedule, including ≥ 80- year-olds. (This paper also includes information on GMTs at different time points post vaccination.) (a) AZ Vaccine Age 50-64





							(b) Pfizer
							Age 50-64 Age 65-79 Age 65-79
							Age 80+ (Vaccinated before Jan 4th 2021)
							Figure 4: Two dose vaccine effectiveness by age group, vaccine type and interval between doses
3	Italian Instituo Superiore di Sanita (July 30, 2021)	Italy	Italian general adult population with at least 1 dose of vaccine	Alpha	BNT162b2 AZD1222 mRNA-1273 Ad26.COV2.S	December 27, 2020- July 14, 2021	This study linked Italy's national vaccination registry with their surveillance data. For each of the outcomes evaluated, a multivariable negative binomial model was used to estimate the incidence rate ratio at different time intervals post dose 1 and 2, compared to the time period of 0-14 days after the first dose. VE is preserved against infection post complete vaccination for BNT162b2 at day 147-154, for mRNA-1273 at day 126-133, for AZD1222 at day 49-56, and for Ad26.COV2.S at day 49-56. VE against hospitalization, ICU admission, and mortality also do not change significantly over time.





							Figure 16. Adjusted estimates of the Incidence Rate Ratio of diagnosis at different time intervals from the first additional second dose compared to the reference period (0-14 days from the first dose) by vaccine brand
2	Israel et al (August 5, 2021)	Israel	All fully vaccinated persons enrolled in Leumit Health Services	Delta	BNT162b2	May 15-July 26, 2021	There was a significantly higher rate of positive results among patients who received their second vaccine dose at least 146 days before the RT-PCR test compared to patients who have received their vaccine less than 146 days before: adjusted odds ratio for infection was 2.76 (95% Cl 1.62-3.08) for ≥ 60-year-old patients; 2.22 (95% Cl 1.62-3.08) for patients 40-59-years; and 1.67 (95% Cl 1.21-2.29) for 18-39-year-old patients.
1	Mizrahi et al (July 31, 2021)	Israel	16+ year olds enrolled at Maccabi Health Services	Delta	BNT162b2	June 1-July 27, 2021	The study compared the rate of breakthrough infection during June and July, when Delta was the dominant strain, between individuals who received 2 doses of the vaccine earlier this year to individuals who received two doses of the vaccine more recently, while adjusting for confounders. The authors report that persons vaccinated between January and February 2021 had a 53% (95% CI: 40-68%) increased risk of breakthrough infection in June and July compared to individuals vaccinated between March and April 2021. There was no difference by age groups 16-39, 40-59, ≥60 years. No unvaccinated persons were included in the study; thus, vaccine effectiveness was not evaluated.

Other data of interest:

- <u>https://www.gov.il/BlobFolder/reports/vpb-12082021/he/files_publications_corona_vpb-12082021-01.pdf</u>
- <u>Salo et al</u> HH transmission study in Finland, showing VE 10 weeks after 1 dose of an mRNA vaccine but is a mix of 1 and 2 dose recipients.
- Pfizer's press announcement of 4 month efficacy in adolescents <u>https://www.pfizer.com/news/press-release/press-release-detail/follow-data-phase-3-trial-pfizer-biontech-covid-19-vaccine</u>

Note as of January 7, 2022 version, only true duration of protection analyses are included. Please look at the <u>update</u> from December 30, 2021 if you wish to see full list of previously included studies with other data such as Kaplan-Meier curves. Missing reference numbers in table above indicate studies that have been removed.